{
    "headline": "Accelerating clinical trials to improve biopharma R&amp;D productivity",
    "link": "https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity",
    "content": "<!DOCTYPE html><html dir=\"ltr\" lang=\"en\"><head><meta charset=\"utf-8\"><meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\"><meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\"><iframe src=\"javascript:void(0)\" title=\"\" role=\"presentation\" style=\"width: 0px; height: 0px; border: 0px; display: none;\"></iframe><script>var McKinsey = {\"ArticleTemplate\":\"Legacy\",\"DaysSinceCMSPublication\":\"254\",\"DisplayDate\":\"1/22/2024\",\"OriginalPublicationDate\":\"1/22/2024\",\"SitecoreId\":\"{B2FCD064-0B5A-441E-99E4-2D8A7BFC375A}\",\"Title\":\"Accelerating clinical trials to improve biopharma R&D productivity\",\"ArticleType\":\"Article\",\"ContentType\":\"Article\",\"ServerNumber\":\"\",\"IsPageRestricted\":\"true\",\"UserID\":\"\",\"RegistrationDate\":\"\",\"LoginStatus\":\"logged_out\",\"JobTitle\":\"\",\"CompanyName\":\"\",\"blogTags\":null}; var pageMetaInformation = {\"CurrentLanguage\":\"en\",\"AlternateLanguages\":[{\"DisplayName\":\"English\",\"LanguageCode\":\"en\",\"Url\":\"/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\"}],\"NavigationLink\":\"industries\",\"ActiveItemId\":\"{BB8498AC-8CC4-4BFB-8832-53C76F3E61CF}\",\"OfficeCode\":\"\",\"MiniSiteId\":\"{CDBF3A89-AE60-459E-ACF8-786E31307534}\"};</script><link rel=\"icon\" href=\"/favicon.ico\"><link href=\"https://www.mckinsey.com/redesign/resources/css/styles-rc.css\" rel=\"stylesheet\"><link rel=\"manifest\" href=\"/manifest.json\"><link rel=\"dns-prefetch\" href=\"//cdn.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//st.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//rcom.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//cdn.cookielaw.org\"><link rel=\"preconnect\" href=\"//assets.adobedtm.com\"><link rel=\"preconnect\" href=\"//connect.facebook.net\"><link rel=\"preconnect\" href=\"//static.hotjar.com\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/bower/Bower-Bold.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/regular/McKinseySans-Regular.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/medium/McKinseySans-Medium.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/light/McKinseySans-Light.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/italic/McKinseySans-Italic.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/light-italic/McKinseySans-LightItalic.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/medium-italic/McKinseySans-MediumItalic.woff2\" type=\"font/woff2\" crossorigin=\"\"><meta name=\"apple-itunes-app\" content=\"app-id=674902075\"><link rel=\"apple-touch-icon\" sizes=\"57x57\" href=\"/next-static/images/mck-touch-icon-57x57.png\"><link rel=\"apple-touch-icon\" sizes=\"72x72\" href=\"/next-static/images/mck-touch-icon-72x72.png\"><link rel=\"apple-touch-icon\" sizes=\"114x114\" href=\"/next-static/images/mck-touch-icon-114x114.png\"><link rel=\"apple-touch-icon\" sizes=\"144x144\" href=\"/next-static/images/mck-touch-icon-144x144.png\"><link rel=\"apple-touch-icon\" sizes=\"152x152\" href=\"/next-static/images/mck-touch-icon-152x152.png\"><link rel=\"apple-touch-icon\" sizes=\"167x167\" href=\"/next-static/images/mck-touch-icon-167x167.png\"><link rel=\"apple-touch-icon\" sizes=\"180x180\" href=\"/next-static/images/mck-touch-icon-180x180.png\"><meta content=\"no-referrer-when-downgrade\" name=\"referrer\"><meta content=\"McKinsey &amp; Company\" property=\"og:site_name\" name=\"site_name\"><meta content=\"Accelerating clinical trials to improve biopharma R&amp;D productivity\" property=\"og:title\" name=\"title\"><meta content=\"Biopharma clinical trial sponsors want to speed up trials through targeted actions to improve patient and site engagement and enrollment productivity\" property=\"og:description\" name=\"description\"><meta content=\"https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\" name=\"url\" property=\"og:url\"><meta content=\"index,follow,all\" name=\"robots\"><meta content=\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/accelerating-clinical-trials-thumb-1536x1536.jpg\" property=\"og:image\" name=\"image\"><meta content=\"{B2FCD064-0B5A-441E-99E4-2D8A7BFC375A}\" name=\"sid\"><link href=\"https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\" rel=\"canonical\"><meta content=\"Life Sciences\" name=\"practice-name\"><meta content=\"N20\" name=\"practice-code\"><meta content=\"summary_large_image\" name=\"twitter:card\"><meta content=\"@mckinsey\" name=\"twitter:site\"><title>Speed up biopharma clinical trials to boost R&amp;D output | McKinsey</title><meta content=\"Insights &amp; Publications\" name=\"sections\"><meta content=\"Accelerating clinical trials to improve biopharma R&amp;amp;D productivity\" name=\"twitter:title\"><meta content=\"Biopharma clinical trial sponsors want to speed up trials through targeted actions to improve patient and site engagement and enrollment productivity\" name=\"twitter:description\"><meta content=\"Article\" property=\"contenttype\" name=\"contenttype\"><meta content=\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/accelerating-clinical-trials-thumb-1536x1536.jpg?mw=677&amp;car=42:25\" name=\"twitter:image\"><meta content=\"Accelerating clinical trials to improve biopharma R&amp;D productivity\" name=\"twitter:image:alt\"><meta content=\"true\" name=\"mobileready\"><meta content=\"public\" name=\"accesslevel\"><meta content=\"false\" name=\"excludefromclientlink\"><meta content=\"article\" name=\"articletype\"><meta content=\"Gaurav Agrawal | Harriet Keane | Brandon Parry | Valentina Sartori | Jacob Kautzky | Amy Silverstein\" name=\"authors-name\"><meta content=\"2024-01-22T00:00:00Z\" name=\"itemdate\"><meta content=\"Life Sciences | Article | January 22, 2024\" name=\"searchresults-tags\"><script type=\"application/ld+json\">{\"@context\":\"https://schema.org\",\"@type\":\"Article\",\"url\":\"https://www.mckinsey.com\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"McKinsey & Company\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https://www.mckinsey.com/~/media/Thumbnails/Mck_Logo\"}},\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\"},\"datePublished\":\"2024-01-22T00:00:00Z\",\"dateCreated\":\"2024-01-09T15:53:24Z\",\"dateModified\":\"2024-01-22T00:00:00Z\",\"heading\":\"Accelerating clinical trials to improve biopharma R&amp;D productivity\",\"image\":\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/accelerating-clinical-trials-thumb-1536x1536.jpg\",\"description\":\"Biopharma clinical trial sponsors want to speed up trials through targeted actions to improve patient and site engagement and enrollment productivity\",\"author\":[{\"@type\":\"Person\",\"name\":\"Gaurav Agrawal\",\"url\":\"https://www.mckinsey.com/our-people/gaurav-agrawal\"},{\"@type\":\"Person\",\"name\":\"Harriet Keane\",\"url\":\"https://www.mckinsey.com/our-people/harriet-keane\"},{\"@type\":\"Person\",\"name\":\"Brandon Parry\",\"url\":\"https://www.mckinsey.com/our-people/brandon-parry\"},{\"@type\":\"Person\",\"name\":\"Valentina Sartori\",\"url\":\"https://www.mckinsey.com/our-people/valentina-sartori\"},{\"@type\":\"Person\",\"name\":\"Jacob Kautzky\"},{\"@type\":\"Person\",\"name\":\"Amy Silverstein\"}]}</script><meta charset=\"utf-8\"><meta name=\"next-head-count\" content=\"58\"><meta name=\"next-font-preconnect\"><script src=\"\" id=\"onetrust-wrapperchecker\" data-nscript=\"beforeInteractive\">function OptanonWrapperChecker() {}</script><link rel=\"preload\" href=\"/_next/static/css/2fad2c5744177bb8.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/2fad2c5744177bb8.css\" data-n-g=\"\"><link rel=\"preload\" href=\"/_next/static/css/dc5a0fd9c531d8ae.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/dc5a0fd9c531d8ae.css\" data-n-p=\"\"><link rel=\"preload\" href=\"/_next/static/css/529ed6e2fac958b2.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/529ed6e2fac958b2.css\"><link rel=\"preload\" href=\"/_next/static/css/72fc56b1fbe032aa.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/72fc56b1fbe032aa.css\"><link rel=\"preload\" href=\"/_next/static/css/06ae37db5ebc260c.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/06ae37db5ebc260c.css\"><link rel=\"preload\" href=\"/_next/static/css/5e45d445fc213154.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/5e45d445fc213154.css\"><noscript data-n-css=\"\"></noscript><script defer=\"\" nomodule=\"\" src=\"/_next/static/chunks/polyfills-5cd94c89d3acac5f.js\"></script><script src=\"https://cdn.cookielaw.org/scripttemplates/otSDKStub.js\" data-document-language=\"true\" type=\"text/javascript\" data-domain-script=\"915b5091-0d7e-44d2-a8c4-cf08267e52fe\" defer=\"\" data-nscript=\"beforeInteractive\"></script><script defer=\"\" src=\"/_next/static/chunks/281.674cd4210cb46873.js\"></script><script defer=\"\" src=\"/_next/static/chunks/6731.9bccca8a7edb0704.js\"></script><script defer=\"\" src=\"/_next/static/chunks/2354.05223bcb67691d75.js\"></script><script defer=\"\" src=\"/_next/static/chunks/8578.3a4bfe7b76c8d5b2.js\"></script><script defer=\"\" src=\"/_next/static/chunks/8391.a64dec5b7b976b97.js\"></script><script src=\"/_next/static/chunks/webpack.47afe4b83145c95f.js\" defer=\"\"></script><script src=\"/_next/static/chunks/framework.62bbe2ca94854a85.js\" defer=\"\"></script><script src=\"/_next/static/chunks/main.51e10588adc949ca.js\" defer=\"\"></script><script src=\"/_next/static/chunks/pages/_app.e3dd57df2dc16789.js\" defer=\"\"></script><script src=\"/_next/static/chunks/3b1baa31.cd6cdac6158774d8.js\" defer=\"\"></script><script src=\"/_next/static/chunks/7d0bf13e.8f3383787afb45af.js\" defer=\"\"></script><script src=\"/_next/static/chunks/1354.c34ddc4bd7c986c8.js\" defer=\"\"></script><script src=\"/_next/static/chunks/408.9bf4e4647a127fd0.js\" defer=\"\"></script><script src=\"/_next/static/chunks/pages/%5B%5B...path%5D%5D.99501948ed14e00a.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_buildManifest.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_ssgManifest.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_middlewareManifest.js\" defer=\"\"></script>\n<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push([\"addVar\",{\"rua.upush\":\"false\",\"rua.cpush\":\"false\",\"rua.upre\":\"false\",\"rua.cpre\":\"false\",\"rua.uprl\":\"false\",\"rua.cprl\":\"false\",\"rua.cprf\":\"false\",\"rua.trans\":\"SJ-b7ca1abb-ecba-4149-9919-3f315fab5f35\",\"rua.cook\":\"true\",\"rua.ims\":\"false\",\"rua.ufprl\":\"false\",\"rua.cfprl\":\"false\",\"rua.isuxp\":\"false\",\"rua.texp\":\"norulematch\",\"rua.ceh\":\"false\",\"rua.ueh\":\"false\",\"rua.ieh.st\":\"0\"}]);</script>\n                              <script>!function(a){var e=\"https://s.go-mpulse.net/boomerang/\",t=\"addEventListener\";if(\"False\"==\"True\")a.BOOMR_config=a.BOOMR_config||{},a.BOOMR_config.PageParams=a.BOOMR_config.PageParams||{},a.BOOMR_config.PageParams.pci=!0,e=\"https://s2.go-mpulse.net/boomerang/\";if(window.BOOMR_API_key=\"TURRK-8ADJT-WDUC5-TC32E-KV9ND\",function(){function n(e){a.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!a.BOOMR||!a.BOOMR.version&&!a.BOOMR.snippetExecuted){a.BOOMR=a.BOOMR||{},a.BOOMR.snippetExecuted=!0;var i,_,o,r=document.createElement(\"iframe\");if(a[t])a[t](\"load\",n,!1);else if(a.attachEvent)a.attachEvent(\"onload\",n);r.src=\"javascript:void(0)\",r.title=\"\",r.role=\"presentation\",(r.frameElement||r).style.cssText=\"width:0;height:0;border:0;display:none;\",o=document.getElementsByTagName(\"script\")[0],o.parentNode.insertBefore(r,o);try{_=r.contentWindow.document}catch(O){i=document.domain,r.src=\"javascript:var d=document.open();d.domain='\"+i+\"';void(0);\",_=r.contentWindow.document}_.open()._l=function(){var a=this.createElement(\"script\");if(i)this.domain=i;a.id=\"boomr-if-as\",a.src=e+\"TURRK-8ADJT-WDUC5-TC32E-KV9ND\",BOOMR_lstart=(new Date).getTime(),this.body.appendChild(a)},_.write(\"<bo\"+'dy onload=\"document._l();\">'),_.close()}}(),\"\".length>0)if(a&&\"performance\"in a&&a.performance&&\"function\"==typeof a.performance.setResourceTimingBufferSize)a.performance.setResourceTimingBufferSize();!function(){if(BOOMR=a.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var e=\"false\"==\"true\"?1:0,t=\"cookiepresent\",n=\"ajsxrwycc6kamzy2opnq-f-72a67baa8-clientnsv4-s.akamaihd.net\",i=\"false\"==\"true\"?2:1,_={\"ak.v\":\"39\",\"ak.cp\":\"19387\",\"ak.ai\":parseInt(\"285213\",10),\"ak.ol\":\"0\",\"ak.cr\":15,\"ak.ipv\":4,\"ak.proto\":\"h2\",\"ak.rid\":\"4927ce\",\"ak.r\":49473,\"ak.a2\":e,\"ak.m\":\"a\",\"ak.n\":\"essl\",\"ak.bpcip\":\"2.101.120.0\",\"ak.cport\":63914,\"ak.gh\":\"2.21.6.28\",\"ak.quicv\":\"\",\"ak.tlsv\":\"tls1.3\",\"ak.0rtt\":\"\",\"ak.0rtt.ed\":\"\",\"ak.csrc\":\"-\",\"ak.acc\":\"\",\"ak.t\":\"1729786843\",\"ak.ak\":\"hOBiQwZUYzCg5VSAfCLimQ==KhTnzLuh/f2cj0uWBnWdC4s3WS6nXuZkAB4ICor+LmwANiCB27AIozA8Od0ctPUaz3sPHCPoz4sMTlWAh7/24lnIzYL7qZc8J7XPMC11yr7RO4SYGyi1fVpIPQC9Ppn1BUBFOQ/ZWrIxuv/acRl2/JamYWWYYRcEpFOHd8z8PC23b95BiUWfgqbR+XMmyXalpCEGRzVaeff8A9GjhfM82ozqwEYWqhIB3doZMmJSe69gKOMBnYb08kBv/kGhq228U6GaV5DwluIRV2qu/jyOvP3BUpHiYz18XksQO8LtY9mz+Wbxx9XD5wFxI8CzcyF2QF6cuE26Q0HWG/P0fPEgy4iLUwKTdiyg98pjZHCPs9HIQDuqf2/aggcT9xhDLauymXeiUPHd1Os4AC/X9VHWstrIOpfvI7F6wzA/FCkz02s=\",\"ak.pv\":\"570\",\"ak.dpoabenc\":\"\",\"ak.tf\":i};if(\"\"!==t)_[\"ak.ruds\"]=t;var o={i:!1,av:function(e){var t=\"http.initiator\";if(e&&(!e[t]||\"spa_hard\"===e[t]))_[\"ak.feo\"]=void 0!==a.aFeoApplied?1:0,BOOMR.addVar(_)},rv:function(){var a=[\"ak.bpcip\",\"ak.cport\",\"ak.cr\",\"ak.csrc\",\"ak.gh\",\"ak.ipv\",\"ak.m\",\"ak.n\",\"ak.ol\",\"ak.proto\",\"ak.quicv\",\"ak.tlsv\",\"ak.0rtt\",\"ak.0rtt.ed\",\"ak.r\",\"ak.acc\",\"ak.t\",\"ak.tf\"];BOOMR.removeVar(a)}};BOOMR.plugins.AK={akVars:_,akDNSPreFetchDomain:n,init:function(){if(!o.i){var a=BOOMR.subscribe;a(\"before_beacon\",o.av,null,null),a(\"onbeacon\",o.rv,null,null),o.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><style type=\"text/css\">.mdc-c-button___U4iY2_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border:var(--mdc-size-border-width-1) solid #0000;border-radius:0;color:var(--text-color-default);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}.mdc-c-button___U4iY2_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--primary___Ed-lT_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;background-color:var(--button-primary-background);border:var(--mdc-size-border-width-1) solid #0000;border-radius:0;color:var(--button-primary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--primary___Ed-lT_990311c:hover{background-color:var(--button-primary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--primary___Ed-lT_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--primary___Ed-lT_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text)}.mdc-c-button--primary___Ed-lT_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text);color:var(--button-primary-background)}@media (hover:hover){.mdc-c-button--primary___Ed-lT_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text-hover)}.mdc-c-button--primary___Ed-lT_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text-hover);color:var(--button-primary-background-hover)}}.mdc-c-button--primary___Ed-lT_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text)}.mdc-c-button--primary___Ed-lT_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text);color:var(--button-primary-background)}.mdc-c-button--secondary___Boipq_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;background-color:var(--button-primary-background);background-color:var(--button-secondary-background);border:var(--mdc-size-border-width-1) solid var(--button-secondary-border);border-radius:0;color:var(--button-primary-text);color:var(--button-secondary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--secondary___Boipq_990311c:hover{background-color:var(--button-primary-background-hover);background-color:var(--button-secondary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);border:var(--mdc-size-border-width-1) solid var(--button-secondary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);color:var(--button-secondary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--secondary___Boipq_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--secondary___Boipq_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text);line-height:1}.mdc-c-button--secondary___Boipq_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text);color:var(--mdc-color-neutral-white)}@media (hover:hover){.mdc-c-button--secondary___Boipq_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text-hover)}.mdc-c-button--secondary___Boipq_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text-hover);color:var(--button-secondary-background-hover)}}.mdc-c-button--secondary___Boipq_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text)}.mdc-c-button--secondary___Boipq_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text);color:var(--button-secondary-icon-focus)}.mdc-c-button--tertiary___zPM6q_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:var(--button-primary-background);background-color:initial;border:var(--mdc-size-border-width-1) solid var(--button-tertiary-border);border-radius:0;color:var(--button-primary-text);color:var(--button-tertiary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--tertiary___zPM6q_990311c:hover{background-color:var(--button-primary-background-hover);background-color:var(--button-tertiary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);border:var(--mdc-size-border-width-1) solid var(--button-tertiary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);color:var(--button-tertiary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--tertiary___zPM6q_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--tertiary___zPM6q_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text)}.mdc-c-button--tertiary___zPM6q_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text);color:var(--button-tertiary-text-hover)}@media (hover:hover){.mdc-c-button--tertiary___zPM6q_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text-hover)}.mdc-c-button--tertiary___zPM6q_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text-hover);color:var(--button-tertiary-text)}}.mdc-c-button--tertiary___zPM6q_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text)}.mdc-c-button--tertiary___zPM6q_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text);color:var(--button-tertiary-text-hover)}.mdc-c-button--minimal___Uzgaz_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-primary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal___Uzgaz_990311c:hover{border-bottom-color:var(--button-minimal-primary)}}.mdc-c-button--minimal___Uzgaz_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal___Uzgaz_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal___Uzgaz_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--minimal-secondary___W0Qrc_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-secondary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal-secondary___W0Qrc_990311c:hover{border-bottom-color:var(--button-minimal-secondary)}}.mdc-c-button--minimal-secondary___W0Qrc_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal-secondary___W0Qrc_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal-secondary___W0Qrc_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--minimal-tertiary___YwyAF_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-tertiary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal-tertiary___YwyAF_990311c:hover{border-bottom-color:var(--button-minimal-tertiary-hover);color:var(--button-minimal-tertiary-hover)}}.mdc-c-button--minimal-tertiary___YwyAF_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal-tertiary___YwyAF_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal-tertiary___YwyAF_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--size-large___jwpUy_990311c{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28);min-height:var(--mdc-size-spacing-48);padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-24)}.mdc-c-button--size-small___uvMIB_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);min-height:var(--mdc-size-spacing-32);min-width:var(--mdc-size-spacing-72);padding:var(--mdc-size-spacing-4) var(--mdc-size-spacing-16)}.mdc-c-button--btn-compact___P-iHa_990311c{min-width:auto}.mdc-c-button--disabled___Xbyp5_990311c{border:none!important;cursor:not-allowed}.mdc-c-button--disabled___Xbyp5_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c:hover{border:none!important;box-shadow:none!important;outline:none!important;transform:none!important}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--primary___Ed-lT_990311c{background-color:var(--button-primary-disabled-background);color:var(--button-disabled-text)}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c{background-color:var(--button-secondary-disabled-background);border:var(--mdc-size-border-width-1) solid var(--button-secondary-disabled-border)!important;color:var(--button-disabled-text)}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:hover,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:hover{border:var(--mdc-size-border-width-1) solid var(--button-secondary-disabled-border)!important}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal-secondary___W0Qrc_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal-tertiary___YwyAF_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal___Uzgaz_990311c{color:var(--button-minimal-disabled)}</style><style type=\"text/css\">.mdc-c-link-cta___NBQVi_990311c,.mdc-c-link-icon___SEKyg_990311c,.mdc-c-link-inline___7DRrt_990311c,.mdc-c-link___lBbY1_990311c{align-items:center;color:currentcolor;display:inline-flex;gap:var(--mdc-size-spacing-8)}.mdc-c-link-cta___NBQVi_990311c:focus-visible,.mdc-c-link-icon___SEKyg_990311c:focus-visible,.mdc-c-link-inline___7DRrt_990311c:focus-visible,.mdc-c-link___lBbY1_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--link-color-selected);outline-offset:var(--mdc-size-border-width-4)}.mdc-c-link___lBbY1_990311c{color:var(--link-color-default);text-decoration:none}.mdc-c-link___lBbY1_990311c:focus .mdc-c-link__label___Pfqtd_990311c,.mdc-c-link___lBbY1_990311c:hover .mdc-c-link__label___Pfqtd_990311c{text-decoration-line:underline;text-decoration-thickness:calc(var(--mdc-size-spacing-4)/2);text-underline-offset:calc(var(--mdc-size-spacing-4)/2)}.mdc-c-link--secondary___TSFam_990311c{color:var(--link-color-secondary-default)}.mdc-c-link-inline___7DRrt_990311c{border-bottom:2px solid var(--link-inline-default-border-color);color:currentcolor;line-height:1;padding-left:calc(var(--mdc-size-spacing-4)/2);padding-right:calc(var(--mdc-size-spacing-4)/2);text-decoration:none;transition:.12s linear;transition-property:background-color,color}.mdc-c-link-inline___7DRrt_990311c:hover{background-color:var(--link-inline-default-background-hover-color);border-color:var(--link-inline-default-border-hover-color);color:var(--link-inline-default-hover-color);text-decoration:none}.mdc-c-link-inline--secondary___YKoOK_990311c{border-bottom-color:initial}.mdc-c-link-inline--secondary___YKoOK_990311c:hover{background-color:var(--link-inline-secondary-background-hover-color);border-bottom-color:var(--link-inline-secondary-background-hover-color);color:var(--link-inline-secondary-hover-color)}.mdc-c-link-cta___NBQVi_990311c{color:var(--link-color-text-default);display:inline-block;font-weight:var(--mdc-font-weight-medium)}.mdc-c-link-cta___NBQVi_990311c span[class$=icon]{padding-left:var(--mdc-size-spacing-8);padding-right:var(--mdc-size-spacing-16);transition:padding .4s ease-in-out;vertical-align:initial}.mdc-c-link-cta___NBQVi_990311c span[class$=icon]:before{color:var(--link-cta-icon-color)}.mdc-c-link-cta___NBQVi_990311c:active,.mdc-c-link-cta___NBQVi_990311c:focus,.mdc-c-link-cta___NBQVi_990311c:hover{color:var(--link-color-text-default-hover)}.mdc-c-link-cta___NBQVi_990311c:active span[class$=icon],.mdc-c-link-cta___NBQVi_990311c:focus span[class$=icon],.mdc-c-link-cta___NBQVi_990311c:hover span[class$=icon]{padding-left:var(--mdc-size-spacing-24);padding-right:0}.mdc-c-link-cta--size-large___udJoH_990311c{font-size:var(--mdc-size-font-20);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-32)}@media (min-width:1180px){.mdc-c-link-cta--size-large___udJoH_990311c{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}.mdc-c-link-cta--size-large___udJoH_990311c span[class$=icon]{padding-left:var(--mdc-size-spacing-16);padding-right:var(--mdc-size-spacing-32);transition:padding .4s ease-in-out;vertical-align:initial}.mdc-c-link-cta--size-large___udJoH_990311c span[class$=icon]:before{color:var(--link-cta-icon-color)}.mdc-c-link-cta--size-large___udJoH_990311c:active,.mdc-c-link-cta--size-large___udJoH_990311c:focus,.mdc-c-link-cta--size-large___udJoH_990311c:hover{color:var(--link-color-text-default-hover)}.mdc-c-link-cta--size-large___udJoH_990311c:active span[class$=icon],.mdc-c-link-cta--size-large___udJoH_990311c:focus span[class$=icon],.mdc-c-link-cta--size-large___udJoH_990311c:hover span[class$=icon]{padding-left:var(--mdc-size-spacing-48);padding-right:0}}.mdc-c-link-icon___SEKyg_990311c{color:var(--link-icon-color)}.mdc-c-link-icon___SEKyg_990311c:focus,.mdc-c-link-icon___SEKyg_990311c:hover{color:var(--link-icon-hover-color)}.mdc-c-link-icon___SEKyg_990311c:focus [class^=\"mdc-c-icon--radial::before\"],.mdc-c-link-icon___SEKyg_990311c:hover [class^=\"mdc-c-icon--radial::before\"]{background-color:var(--link-icon-hover-color);color:var(--link-icon-radial-hover-color)}.mdc-c-link-icon___SEKyg_990311c:focus .mdc-c-link__label___Pfqtd_990311c,.mdc-c-link-icon___SEKyg_990311c:hover .mdc-c-link__label___Pfqtd_990311c{text-decoration-line:underline}.mdc-c-link-heading___Zggl8_990311c{color:var(--link-heading-color);font-weight:var(--mdc-font-weight-medium)}.mdc-c-link-heading___Zggl8_990311c:focus,.mdc-c-link-heading___Zggl8_990311c:hover{color:var(--link-heading-hover-color);text-decoration-line:underline;text-decoration-thickness:.07em;text-underline-offset:var(--mdc-size-spacing-4)}.mdc-c-link-heading___Zggl8_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--link-color-selected);outline-offset:var(--mdc-size-border-width-4)}.mdc-c-link-heading--with-icon___ssPll_990311c{display:inline;padding-right:var(--mdc-size-spacing-8)}</style><style type=\"text/css\">.mdc-c-toast__wrapper--active___FhXwN_990311c{z-index:9999}.mdc-c-toast__wrapper--active___FhXwN_990311c>*{pointer-events:auto}.mdc-c-toast__content___aJ0xH_990311c{background:var(--mdc-color-neutral-white);box-shadow:0 7px 14px 0 #0003;max-width:min(100%,var(--mdc-breakpoint-md));padding:var(--mdc-size-spacing-16);pointer-events:auto;will-change:transform}.mdc-c-toast__alert-container___bP-MJ_990311c{padding:0!important}.mdc-c-toast__alert___xdRqn_990311c{background-color:var(--mdc-color-neutral-white)!important;border-color:var(--mdc-color-neutral-gray-06)!important;max-width:min(100%,var(--mdc-breakpoint-lg))}.mdc-c-toast__alert___xdRqn_990311c [data-component=mdc-c-icon]:focus:before,.mdc-c-toast__alert___xdRqn_990311c [data-component=mdc-c-icon]:hover:before{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-toast__message___r6An3_990311c{color:inherit;display:flex;flex:1 1 auto;justify-content:center;white-space:pre-line}</style><style type=\"text/css\">.mdc-c-module-wrapper--full-page___3XZ1n_990311c{align-items:center;display:flex;height:100dvh;justify-content:center;left:0;margin:0!important;padding:0!important;top:0;width:100vw}.mdc-c-module-wrapper--full-page___3XZ1n_990311c img:first-of-type,.mdc-c-module-wrapper--full-page___3XZ1n_990311c video:first-of-type,.mdc-c-module-wrapper--full-page___3XZ1n_990311c>.image___T6Mcc_990311c,.mdc-c-module-wrapper--full-page___3XZ1n_990311c>.mdc-c-bg-image___z77CN_990311c{height:100%;object-fit:cover;width:100%}.story-wrapper{padding:0!important}</style><style type=\"text/css\">:root .mdc-c-icon-svg___68K-O_990311c,[data-module-theme=light] .mdc-c-icon-svg___68K-O_990311c{--icon-svg-stroke-color:currentcolor;--icon-svg-fill-color:none}[data-module-theme=dark] .mdc-c-icon-svg___68K-O_990311c{--icon-svg-stroke-color:var(--mdc-color-neutral-white);--icon-svg-fill-color:none}.mdc-c-icon-svg___68K-O_990311c{display:inline-flex}.mdc-c-icon-svg___68K-O_990311c svg{fill:var(--icon-svg-fill-color)}</style><style type=\"text/css\">:root .mdc-c-icon___oi7ef_990311c,[data-module-theme=light] .mdc-c-icon___oi7ef_990311c{--icon-radial-color:var(--mdc-color-neutral-white);--icon-radial-background-color:var(--mdc-color-neutral-black);--icon-radial-background-color-hover:var(--mdc-color-palette-electric-blue)}[data-module-theme=dark] .mdc-c-icon___oi7ef_990311c{--icon-radial-color:var(--mdc-color-neutral-black);--icon-radial-background-color:var(--mdc-color-neutral-white);--icon-radial-background-color-hover:var(--mdc-color-palette-cyan)}:root .mdc-c-icon--secondary___dSlsG_990311c,[data-module-theme=light] .mdc-c-icon--secondary___dSlsG_990311c{--icon-radial-color:var(--mdc-color-neutral-black);--icon-radial-background-color:unset;--icon-radial-background-color-hover:var(--mdc-color-neutral-gray-06)}[data-module-theme=dark] .mdc-c-icon--secondary___dSlsG_990311c{--icon-radial-color:var(--mdc-color-neutral-white);--icon-radial-background-color:unset;--icon-radial-background-color-hover:var(--mdc-color-palette-cyan)}.mdc-c-icon___oi7ef_990311c{display:inline;line-height:inherit;vertical-align:middle}.mdc-c-icon___oi7ef_990311c:before{color:currentcolor;vertical-align:middle}.mdc-c-icon--outline___MU0j1_990311c:before,.mdc-c-icon--radial___y3csX_990311c:before,.mdc-c-icon-default___0TDAM_990311c:before{font-size:inherit;position:relative}.mdc-c-icon--outline___MU0j1_990311c:hover span,.mdc-c-icon--radial___y3csX_990311c:hover span,.mdc-c-icon-default___0TDAM_990311c:hover span{border-color:inherit;color:inherit}.mdc-c-icon--default___f-hQM_990311c:before{display:block}.mdc-c-icon--outline___MU0j1_990311c:before,.mdc-c-icon--radial___y3csX_990311c:before{align-items:center;border-radius:50%;display:inline-flex;flex-shrink:0;font-size:.5em;height:var(--mdc-size-icon-16);justify-content:center;width:var(--mdc-size-icon-16)}a .mdc-c-icon--outline___MU0j1_990311c:only-child:before,a .mdc-c-icon--radial___y3csX_990311c:only-child:before{transition:.12s linear;transition-property:all}a .mdc-c-icon--outline___MU0j1_990311c:hover:only-child:before,a .mdc-c-icon--radial___y3csX_990311c:hover:only-child:before{box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--icon-radial-background-color);color:var(--icon-radial-color)}a .mdc-c-icon--radial___y3csX_990311c:hover:before,button .mdc-c-icon--radial___y3csX_990311c:hover:before{background-color:var(--icon-radial-background-color-hover)}a:focus .mdc-c-icon--radial___y3csX_990311c:before,a:hover .mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--link-icon-hover-color);color:var(--link-icon-radial-hover-color)}.mdc-c-icon--success___2CfF7_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--mdc-color-status-dark-green);color:var(--mdc-color-neutral-white)}.mdc-c-icon--error___3PoQX_990311c:before{color:var(--mdc-color-status-dark-red)}.mdc-c-icon--error___3PoQX_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--mdc-color-status-dark-red);color:var(--mdc-color-neutral-white)}.mdc-c-icon--info___fsGGT_990311c:before{color:var(--mdc-color-palette-electric-blue)}.mdc-c-icon--warning___iP6zl_990311c:before{color:var(--mdc-color-status-dark-yellow)}.mdc-c-icon--active___4KblW_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--icon-radial-background-color-hover)}.mdc-c-icon--active___4KblW_990311c.mdc-c-icon--outline___MU0j1_990311c:before{background-color:unset;border:var(--mdc-size-border-width-1) solid var(--icon-radial-background-color-hover);color:var(--icon-radial-background-color-hover)}a .mdc-c-icon--secondary___dSlsG_990311c.mdc-c-icon--radial___y3csX_990311c:only-child:before{transition:none}a .mdc-c-icon--secondary___dSlsG_990311c.mdc-c-icon--radial___y3csX_990311c:hover:only-child:before{box-shadow:none;transform:none}.mdc-c-icon--outline___MU0j1_990311c:before{border:var(--mdc-size-border-width-1) solid;border-radius:50%;font-size:.5em}.mdc-c-icon--size-xs___g8-q5_990311c{font-size:var(--mdc-size-icon-10)}.mdc-c-icon--size-xs___g8-q5_990311c:before{height:var(--mdc-size-icon-10);width:var(--mdc-size-icon-10)}.mdc-c-icon--size-sm___2FLYH_990311c{font-size:var(--mdc-size-icon-12)}.mdc-c-icon--size-sm___2FLYH_990311c:before{height:var(--mdc-size-icon-12);width:var(--mdc-size-icon-12)}.mdc-c-icon--size-md___yi5fA_990311c{font-size:var(--mdc-size-icon-16)}.mdc-c-icon--size-md___yi5fA_990311c:before{height:var(--mdc-size-icon-16);width:var(--mdc-size-icon-16)}.mdc-c-icon--size-lg___5rPck_990311c{font-size:var(--mdc-size-icon-24)}.mdc-c-icon--size-lg___5rPck_990311c:before{height:var(--mdc-size-icon-24);width:var(--mdc-size-icon-24)}.mdc-c-icon--size-xl___3BEee_990311c{font-size:var(--mdc-size-icon-32)}.mdc-c-icon--size-xl___3BEee_990311c:before{height:var(--mdc-size-icon-32);width:var(--mdc-size-icon-32)}.mdc-c-icon--size-xxl___cL3ZT_990311c{font-size:var(--mdc-size-icon-40)}.mdc-c-icon--size-xxl___cL3ZT_990311c:before{height:var(--mdc-size-icon-40);width:var(--mdc-size-icon-40)}.mdc-c-icon--align-right___94-AR_990311c{order:2}.mdc-c-content-icon--size-sm___2acYB_990311c,.mdc-c-content-icon--size-xs___hPSY1_990311c{font-size:var(--mdc-size-font-16)}.mdc-c-content-icon--size-md___U5-qz_990311c{font-size:var(--mdc-size-font-24)}.mdc-c-content-icon--size-lg___ALqld_990311c{font-size:var(--mdc-size-font-28)}.mdc-c-content-icon--size-xl___4LKWE_990311c{font-size:var(--mdc-size-font-36)}.mdc-c-content-icon--size-xxl___PB38p_990311c{font-size:var(--mdc-size-font-44)}</style><style type=\"text/css\">.mdc-c-heading___0fM1W_990311c{text-shadow:var(--text-shadow)}.mdc-c-heading--title___5qyOB_990311c{font-family:var(--mdc-font-family-default-primary);font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-medium);letter-spacing:.075rem;line-height:var(--mdc-size-line-height-24);text-transform:uppercase}.mdc-c-heading--title___5qyOB_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--border___K8dj3_990311c{border-top:var(--mdc-size-border-width-1) solid;padding-top:var(--mdc-size-spacing-24)}.mdc-c-heading__icon___TbFKK_990311c{color:var(--link-cta-icon-color);position:absolute}</style><style type=\"text/css\">.mdc-c-description___SrnQP_990311c{text-shadow:var(--text-shadow)}.mdc-c-description___SrnQP_990311c>p:last-child{margin-bottom:0}</style><style type=\"text/css\">.mdc-c-accordion__items___yF0jA_990311c{border-bottom:var(--mdc-size-border-width-1) solid;border-top:var(--mdc-size-border-width-1) solid}.mdc-c-accordion__items--border-0___elAT7_990311c{border:none}.mdc-c-accordion__item___TaDQ0_990311c{word-break:break-word}.mdc-c-accordion__item___TaDQ0_990311c:not(:last-child){border-bottom:var(--mdc-size-border-width-1) solid}.mdc-c-accordion__title-wrapper___ujaRh_990311c{display:block!important;position:relative;text-align:inherit!important;width:100%}.mdc-c-accordion__title-wrapper___ujaRh_990311c:hover div{color:var(--button-minimal-primary)}.mdc-c-accordion__title___S2Csf_990311c{border-bottom:0;display:block;padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-48) var(--mdc-size-spacing-16) 0}.mdc-c-accordion__icon___MnUrM_990311c{position:absolute;right:var(--mdc-size-spacing-16);top:50%;transform:translateY(-50%);width:-webkit-max-content;width:max-content}.mdc-c-accordion__content-wrapper___WBkbu_990311c{padding-bottom:var(--mdc-size-spacing-16)}</style><style type=\"text/css\">.mdc-c-content-block___7p6Lu_990311c{grid-gap:var(--mdc-size-spacing-16);display:grid}.mdc-c-content-block--size-xxl___N8MW3_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-76);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-92)}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-44);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-52)}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-md___ZNL6I_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-md___ZNL6I_990311c [class^=mdc-c-heading]{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}.mdc-c-content-block--size-sm___8ZwhU_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24)}.mdc-c-content-block--size-sm___8ZwhU_990311c [class^=mdc-c-heading]{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--align-center___KRLtu_990311c{text-align:center}.mdc-c-content-block--align-center___KRLtu_990311c [class^=mdc-c-link-container]{justify-content:center;justify-items:center}.mdc-c-content-block--align-right___yCJP2_990311c{text-align:right}.mdc-c-content-block--align-right___yCJP2_990311c [class^=mdc-c-link-container]{justify-content:right;justify-items:right}</style><style type=\"text/css\">.mdc-c-link-container___xefGu_990311c{grid-gap:var(--mdc-size-spacing-16);align-items:flex-start;display:flex;flex-flow:column wrap}.mdc-c-link-container--display-column___X0HDD_990311c{align-items:center!important;flex-flow:row wrap;justify-content:flex-start}.mdc-c-link-container--align-center___ar3mu_990311c{align-items:center;justify-content:center}.mdc-c-link-container--align-right___6XjJx_990311c{align-items:flex-end;justify-content:flex-end}.mdc-c-link-container--display-row___LYWqK_990311c [class^=mdc-c-button]{align-self:stretch;max-width:100%}</style><style type=\"text/css\">.mdc-c-avatar___kVSTP_990311c{align-items:center;display:inline-flex;height:var(--mdc-avatar-size);justify-content:center;width:var(--mdc-avatar-size)}.mdc-c-avatar___kVSTP_990311c a{align-items:center;border-radius:inherit;color:var(--mdc-color-neutral-white);display:flex;height:100%;justify-content:center;overflow:hidden;width:100%}.mdc-c-avatar__hide___rnSnd_990311c{display:none}.mdc-c-avatar___kVSTP_990311c img{border-radius:inherit;height:inherit;width:inherit}.mdc-c-avatar--image___levct_990311c{background-color:var(--mdc-color-neutral-gray-04);border-radius:50%;display:inline-block}.mdc-c-avatar--image-placeholder___BX3C4_990311c{background-image:url(\"data:image/svg+xml;charset=utf-8,%3Csvg width='62' height='62' xmlns='http://www.w3.org/2000/svg'%3E%3Cdefs%3E%3Cfilter id='a'%3E%3CfeColorMatrix in='SourceGraphic' values='0 0 0 0 0.701961 0 0 0 0 0.701961 0 0 0 0 0.701961 0 0 0 1.000000 0'/%3E%3C/filter%3E%3C/defs%3E%3Cg filter='url(%23a)' transform='translate(-1 -1)' fill='%23B3B3B3' fill-rule='evenodd'%3E%3Cpath d='M32 1C14.906 1 1 14.907 1 32s13.906 31 31 31 31-13.907 31-31S49.094 1 32 1ZM20 28c0-6.617 5.383-12 12-12s12 5.383 12 12v3c0 6.617-5.383 12-12 12s-12-5.383-12-12v-3Zm12 33a28.847 28.847 0 0 1-17.789-6.122C17.082 49.99 22.26 47 28 47h8c5.733 0 10.911 2.99 13.788 7.879A28.845 28.845 0 0 1 32 61Z' fill='%23000'/%3E%3C/g%3E%3C/svg%3E\");background-repeat:no-repeat;background-size:contain}.mdc-c-avatar--text___Z2T5E_990311c{align-items:center;background-color:var(--mdc-color-palette-deep-blue);border-radius:50%;color:var(--mdc-color-neutral-white);display:inline-flex;font-weight:var(--mdc-font-weight-regular);justify-content:center}</style><style type=\"text/css\">.mdc-c-header__eyebrow___PZMpI_990311c{display:inline-block;font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);margin-bottom:var(--mdc-size-spacing-8)}.mdc-c-header__block___i1Lg-_990311c{grid-gap:var(--mdc-size-spacing-16);display:grid}</style><style type=\"text/css\">.mdc-c-bg-image___GJdv1_990311c{background-size:cover;min-height:100%}.mdc-c-bg-image--opaque-bg___CauU1_990311c{background-color:var(--mdc-color-neutral-black);bottom:0;left:0;position:absolute;right:0;top:0}</style><style type=\"text/css\">.mdc-c-tooltip___iYQYf_990311c{max-width:90%;min-width:160px;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);position:absolute;text-align:center}@media (min-width:768px){.mdc-c-tooltip___iYQYf_990311c{max-width:500px}}.mdc-c-tooltip--min-width-auto___Na7Bp_990311c{min-width:auto}.mdc-c-tooltip__arrow___BvUKx_990311c{position:absolute;width:15px}.mdc-c-tooltip__arrow--static___tBroH_990311c{bottom:-14px;left:50%;transform:translateX(-50%)}.mdc-c-tooltip--light___3HIZT_990311c{background-color:var(--mdc-color-neutral-white)}.mdc-c-tooltip--light___3HIZT_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-neutral-white)}.mdc-c-tooltip--semi-light___nUvVM_990311c{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-tooltip--semi-light___nUvVM_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-neutral-gray-06)}.mdc-c-tooltip--dark___EVQsg_990311c{background-color:var(--mdc-color-palette-deep-blue)}.mdc-c-tooltip--dark___EVQsg_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-palette-deep-blue)}.mdc-c-tooltip--elevated___KfVi2_990311c{box-shadow:0 7px 14px 0 #0003}</style><style type=\"text/css\">.mdc-c-brand-lines___HsR8E_990311c{height:0;width:0}.mdc-c-brand-lines__line___tr8-f_990311c{background-color:var(--mdc-color-palette-electric-blue);position:absolute}.mdc-c-brand-lines__line--left___tRtEV_990311c{left:0}.mdc-c-brand-lines__line--right___GLoBF_990311c{right:0}.mdc-c-brand-lines__line--top___4jrrn_990311c{top:0}.mdc-c-brand-lines__line--bottom___P7RVL_990311c{bottom:0}.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:20px;width:100%}@media (min-width:768px){.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:25px}}@media (min-width:1180px){.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:30px}}.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{height:100%;width:20px}@media (min-width:768px){.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{width:25px}}@media (min-width:1180px){.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{width:30px}}.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-20px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-20px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-20px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-20px}@media (min-width:768px){.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-25px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-25px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-25px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-30px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-30px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-30px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-30px}}.mdc-c-brand-lines__offset-filler___xRGlR_990311c{background-color:var(--mdc-color-palette-electric-blue);height:20px;position:absolute;width:20px}@media (min-width:768px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{height:25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{height:30px}}@media (min-width:768px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{width:25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{width:30px}}.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-20px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-20px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-20px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-20px}@media (min-width:768px){.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-25px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-25px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-25px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-30px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-30px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-30px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-30px}}</style><style type=\"text/css\">@charset \"UTF-8\";blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c{border-left:none;padding-left:0}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-28);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-40)}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c>p:first-of-type:before{content:\"\";margin-left:-.4em}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c>p:last-of-type:after{content:\"\"}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}@media (min-width:1180px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-44);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-52)}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite span{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite span{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}}blockquote.mdc-c-blockquote--is-align-center___l-q5n_990311c{text-align:center}blockquote.mdc-c-blockquote--is-align-right___yD7vc_990311c{text-align:right}@media (min-width:1180px){blockquote.mdc-c-blockquote--is-not-full-width___Dyvim_990311c{margin:0 auto;width:490px}}blockquote .mdc-c-blockquote__author-name___u4L7-_990311c{display:inline-block;text-decoration:inherit}</style><style type=\"text/css\">.mdc-c-progress-bar___PW5Xi_990311c{height:calc(var(--mdc-size-spacing-40)/2);overflow:hidden;position:relative}.mdc-c-progress-bar__progress___wQRDN_990311c{-webkit-appearance:none;appearance:none;height:inherit;overflow:hidden;position:absolute;width:100%}.mdc-c-progress-bar__progress___wQRDN_990311c::-webkit-progress-bar{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-progress-bar__progress___wQRDN_990311c::-moz-progress-bar{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-progress-bar__progress___wQRDN_990311c::-moz-progress-value{background-color:var(--mdc-color-neutral-gray-54);-moz-transition:width .6s ease-in-out;transition:width .6s ease-in-out}.mdc-c-progress-bar__progress___wQRDN_990311c::-webkit-progress-value{background-color:var(--mdc-color-neutral-gray-54);-webkit-transition:width .6s ease-in-out;transition:width .6s ease-in-out}.mdc-c-progress-bar__label___JDW5s_990311c{color:var(--mdc-color-neutral-white);font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);line-height:var(--mdc-size-line-height-20);position:absolute;top:0;transform:translate(calc(-100% - var(--mdc-size-spacing-8)));transition:left .6s ease-in-out}.mdc-c-progress-bar__label--align-outside___-YOop_990311c{color:var(--mdc-color-neutral-gray-54);padding-left:var(--mdc-size-spacing-8)}</style><style type=\"text/css\">.mdc-c-drop-down__rootmenu___yJzvz_990311c{color:var(--root-share-icon-color)!important;cursor:pointer;display:inline-grid!important;font-size:.75rem!important;font-weight:var(--mdc-font-weight-light)!important;gap:0!important;grid-auto-flow:row!important;line-height:1rem!important}.mdc-c-drop-down__rootmenu___yJzvz_990311c span:before{margin:auto}.mdc-c-drop-down__rootmenu--active___VHnk6_990311c,.mdc-c-drop-down__rootmenu___yJzvz_990311c:hover{color:var(--root-share-icon-color-hover)}.mdc-c-drop-down__menu___z9UVl_990311c{background:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-2);display:grid;gap:var(--mdc-size-spacing-16);padding:var(--mdc-size-spacing-24)}.mdc-c-drop-down__menu___z9UVl_990311c ul{margin:0;padding:0}.mdc-c-drop-down__menu___z9UVl_990311c ul li{list-style-type:none}.mdc-c-drop-down__menu___z9UVl_990311c ul li:not(:last-of-type){margin-bottom:var(--mdc-size-spacing-8)}.mdc-c-drop-down__menuitem___xIPFf_990311c{gap:var(--mdc-size-spacing-8)!important;line-height:1}.mdc-c-drop-down__arrow___O0eKP_990311c{position:absolute;transform:rotate(180deg)}.mdc-c-drop-down__arrow___O0eKP_990311c span{filter:drop-shadow(0 1px .5px rgba(5,28,44,.2));line-height:var(--mdc-size-line-height-24)}.mdc-c-drop-down__arrow___O0eKP_990311c span:before{color:var(--mdc-color-neutral-white)}</style><style type=\"text/css\">.mdc-c-bg-video___KqGb1_990311c{height:100%;object-fit:cover;width:100%}.mdc-c-play-pause-button___dscFo_990311c{bottom:var(--mdc-size-spacing-16);position:absolute;right:var(--mdc-size-spacing-24);z-index:var(--mdc-zindex-1)}.mdc-c-play-pause-button___dscFo_990311c span:before{background-color:var(--mdc-color-neutral-black)!important;color:var(--mdc-color-neutral-white)!important}.mdc-c-play-pause-button___dscFo_990311c span:hover:before{background-color:var(--mdc-color-palette-electric-blue)!important;box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}</style><style type=\"text/css\">.mdc-c-alert___HJ1s1_990311c{align-items:center;display:flex;gap:var(--mdc-size-spacing-8);justify-content:space-between;opacity:var(--mdc-opacity-100);padding:var(--mdc-size-spacing-16);transition-timing-function:ease-out}.mdc-c-alert--close-alert___BZpm3_990311c{opacity:0;transition:.2s}.mdc-c-alert--success___moj-j_990311c{background-color:var(--mdc-color-status-light-green);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-green)}.mdc-c-alert--error___iR23S_990311c{background-color:var(--mdc-color-status-light-red);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-red)}.mdc-c-alert--info___2ifXt_990311c{background-color:var(--mdc-color-status-light-blue);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-blue)}.mdc-c-alert--warning___2vdhU_990311c{background-color:var(--mdc-color-status-light-yellow);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-yellow)}.mdc-c-alert__message___CA3pW_990311c{display:flex;flex:1 1 0%;flex-wrap:wrap;justify-content:space-between}.mdc-c-alert__container___OY1LN_990311c{display:flex;gap:var(--mdc-size-spacing-16)}.mdc-c-alert__alert-icon___UDJog_990311c{flex:1 0 var(--mdc-size-spacing-24)}.mdc-c-alert__close-alert___UNT03_990311c{align-self:baseline;cursor:pointer;flex:0 0 var(--mdc-size-spacing-24)}.mdc-c-alert__close-alert___UNT03_990311c span:before{background-color:initial;color:var(--mdc-color-neutral-black)}.mdc-c-alert__close-alert___UNT03_990311c:focus span:before,.mdc-c-alert__close-alert___UNT03_990311c:hover span:before{background-color:#ffffff4d}</style><style type=\"text/css\">.mdc-c-loader___W8w3-_990311c{animation:spin___HfHqf_990311c 1.4s linear infinite;border:var(--mdc-size-spacing-4) solid var(--loader-border);border-radius:50%;border-top:var(--mdc-size-spacing-4) solid var(--loader-border-top);margin:0 auto}.mdc-c-loader--size-sm___K1ZMm_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-loader--size-md___EAQRY_990311c{height:var(--mdc-size-spacing-48);width:var(--mdc-size-spacing-48)}.mdc-c-loader--size-lg___0hH02_990311c{height:var(--mdc-size-spacing-72);width:var(--mdc-size-spacing-72)}.mdc-c-loader--border-1___w1cAp_990311c{border-width:1px}.mdc-c-loader--border-2___b8kJb_990311c{border-width:2px}.mdc-c-loader--border-3___AeSHf_990311c{border-width:3px}.mdc-c-loader--border-4___AsS32_990311c{border-width:4px}.mdc-c-loader--border-5___JRHFb_990311c{border-width:5px}.mdc-c-loader--inline___laBg6_990311c{margin:0}@keyframes spin___HfHqf_990311c{0%{transform:rotate(0deg)}to{transform:rotate(1turn)}}</style><style type=\"text/css\">.mdc-c-char-counter___vIMEm_990311c{color:var(--mdc-color-neutral-gray-70);font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);margin-left:auto}.mdc-c-char-counter--error___09qgB_990311c{color:var(--mdc-color-status-red)}</style><style type=\"text/css\">.mdc-c-form-control___ib-Ut_990311c{display:flex;flex-direction:column;gap:var(--mdc-size-spacing-8)}.mdc-c-form-control__label___ICXbu_990311c{color:var(--mdc-color-neutral-black);font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-24);margin:0}.mdc-c-form-control--error___9sMf7_990311c{color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__field___PTF2Y_990311c,.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__textarea___3V76M_990311c{border-color:var(--mdc-color-status-red);color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c label{color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__editor___TSbUw_990311c{border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-red);color:var(--mdc-color-status-red)}.mdc-c-form-control--size-sm___OAC6g_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);min-height:var(--mdc-size-spacing-32)}.mdc-c-form-control--size-md___nT0HS_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-42)}.mdc-c-form-control--size-lg___UeotQ_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-48)}.mdc-c-form-control--size-xl___8xbCi_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36);min-height:var(--mdc-size-spacing-56);padding:var(--mdc-size-spacing-24)}.mdc-c-form-control--size-xxl___LoPhp_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36);min-height:var(--mdc-size-spacing-64);padding:var(--mdc-size-spacing-32) var(--mdc-size-spacing-24)}.mdc-c-form-control__text-helper___gGlvN_990311c,.mdc-c-form-control__text-hint___rHwCJ_990311c{color:var(--mdc-color-neutral-gray-54)}.mdc-c-form-control__text-hint___rHwCJ_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-form-control__text-icon___ZRGsL_990311c{line-height:var(--mdc-size-spacing-4);margin-right:var(--mdc-size-spacing-4)}.mdc-c-form-control__text-error___grncf_990311c{color:var(--mdc-color-status-red);font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-form-control__control___oPCjw_990311c{position:relative}.mdc-c-form-control__show-icon___DcQyC_990311c{display:inline-flex;position:absolute;right:var(--mdc-size-spacing-16);top:50%;transform:translateY(-50%)}.mdc-c-form-control__show-icon--icon-left___bTByt_990311c{left:var(--mdc-size-spacing-16);right:inherit}.mdc-c-form-control__info-tooltip-wrapper___WvQ1m_990311c{align-items:center;display:flex;gap:var(--mdc-size-spacing-8)}.mdc-c-form-control___ib-Ut_990311c [class^=mdc-c-tooltip]{color:var(--mdc-color-neutral-gray-54);z-index:var(--mdc-zindex-1)}.mdc-c-form-control__textarea___3V76M_990311c{font-weight:var(--mdc-font-weight-regular);height:96px;max-height:600px}.mdc-c-form-control__textarea___3V76M_990311c.error___gKx3A_990311c{border-color:var(--mdc-color-status-red)}.mdc-c-form-control___ib-Ut_990311c .mdc-c-form-control__field--icon-right___W4s-t_990311c{padding-right:var(--mdc-size-spacing-56)}.mdc-c-form-control___ib-Ut_990311c .mdc-c-form-control__field--icon-left___YoJju_990311c{padding-left:var(--mdc-size-spacing-56)}.mdc-c-form-control__input-bottom___q3J5i_990311c{display:flex;gap:var(--mdc-size-spacing-32);justify-content:space-between}.mdc-c-form-control__input-bottom___q3J5i_990311c .mdc-c-form-control__container___1bzSs_990311c{display:flex;flex-direction:column}</style><style type=\"text/css\">.mdc-c-checkbox-control___UWECp_990311c{align-self:flex-start;cursor:pointer;display:flex;flex-direction:row;padding:var(--mdc-size-spacing-4) 0}.mdc-c-checkbox-control__wrapper___QhZEn_990311c{display:flex;flex-direction:row}.mdc-c-checkbox-control__label-container___xQnnT_990311c{display:flex;flex-direction:column;flex-grow:1;margin-left:var(--mdc-size-spacing-8)}.mdc-c-checkbox-control__hint___A79E-_990311c{overflow:hidden}.mdc-c-checkbox-control__display-name___DpsHy_990311c{font-weight:var(--mdc-font-weight-light);overflow:hidden}.mdc-c-checkbox-control__display-name___DpsHy_990311c span{border-bottom:var(--mdc-size-border-width-2) solid #0000;color:var(--mdc-color-neutral-black);font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24)}.mdc-c-checkbox-control__tooltip-content___a0MS3_990311c{margin-left:var(--mdc-size-spacing-8)}.mdc-c-checkbox-control___UWECp_990311c label.mdc-c-checkbox-control__display-name___DpsHy_990311c{text-transform:none}.mdc-c-checkbox-control___UWECp_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control___UWECp_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c{border-color:var(--mdc-color-palette-electric-blue)}.mdc-c-checkbox-control___UWECp_990311c:focus-within .mdc-c-checkbox-control__display-name___DpsHy_990311c span,.mdc-c-checkbox-control___UWECp_990311c:hover .mdc-c-checkbox-control__display-name___DpsHy_990311c span{border-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-palette-electric-blue);cursor:pointer}.mdc-c-checkbox-control__checkbox___pjkv3_990311c{align-items:center;-webkit-appearance:none;appearance:none;background:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);cursor:pointer;display:flex;flex:0 0 auto;flex-shrink:0;font-family:mck-icons;justify-content:center}.mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{background:var(--mdc-color-palette-electric-blue);border-color:var(--mdc-color-palette-electric-blue)}.mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked:after{color:var(--mdc-color-neutral-white);content:\"\\e612\"}.mdc-c-checkbox-control--size-md___-06Hq_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control--size-sm___z-REr_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-16);width:var(--mdc-size-spacing-16)}.mdc-c-checkbox-control--size-md___-06Hq_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c,.mdc-c-checkbox-control--size-sm___z-REr_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-checkbox-control--size-lg___1E9cE_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-24);width:var(--mdc-size-spacing-24)}.mdc-c-checkbox-control--size-xl___FfdJO_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-checkbox-control--size-xl___FfdJO_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-checkbox-control--size-xxl___YZHt-_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{font-size:var(--mdc-size-font-24);font-weight:bolder;height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-line-height-36);width:var(--mdc-size-spacing-40)}.mdc-c-checkbox-control--size-xxl___YZHt-_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c{border-color:var(--mdc-color-neutral-gray-30)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{border-color:var(--mdc-color-status-light-blue)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__display-name___DpsHy_990311c span,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__display-name___DpsHy_990311c span{border:none;color:var(--mdc-color-neutral-gray-30);cursor:not-allowed}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{background:var(--mdc-color-neutral-gray-18);border-color:var(--mdc-color-neutral-gray-30);cursor:not-allowed}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c span{color:var(--mdc-color-neutral-gray-30)}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{background:var(--mdc-color-status-light-blue);border-color:var(--mdc-color-status-light-blue)}.mdc-c-checkbox-group___K-viM_990311c{display:flex}.mdc-c-checkbox-group--direction-row___vFCK9_990311c{flex-direction:row;gap:var(--mdc-size-spacing-8);justify-content:flex-start}.mdc-c-checkbox-group--direction-column___VeWCA_990311c{align-items:flex-start;flex-direction:column;gap:var(--mdc-size-spacing-4)}</style><style type=\"text/css\">.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);cursor:pointer;font-family:mck-icons;opacity:0;position:absolute}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:not(:checked)+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c{display:none}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c{display:block}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c:before{background-color:var(--mdc-color-palette-electric-blue)}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label{cursor:pointer}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label span:before,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label span:before{box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c{border-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-palette-electric-blue)}.mdc-c-radial-checkbox-control--size-md___sYwDS_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c,.mdc-c-radial-checkbox-control--size-sm___FGVel_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-16);width:var(--mdc-size-spacing-16)}.mdc-c-radial-checkbox-control--size-lg___o6P1-_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-24);width:var(--mdc-size-spacing-24)}.mdc-c-radial-checkbox-control--size-xl___xTUNR_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-radial-checkbox-control--size-xxl___uDI7N_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{font-size:var(--mdc-size-font-24);font-weight:bolder;height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-line-height-36);width:var(--mdc-size-spacing-40)}</style><style type=\"text/css\">.mdc-c-tag___bvVWv_990311c{align-items:center;background-color:var(--mdc-color-neutral-gray-18);border-radius:var(--mdc-size-border-radius-4);color:var(--mdc-color-neutral-black);display:flex;font-family:var(--mdc-font-family-default-primary);font-size:var(--mdc-size-font-12);font-weight:var(--mdc-font-weight-light);gap:var(--mdc-size-spacing-8);line-height:var(--mdc-size-line-height-16);padding:var(--mdc-size-spacing-8);width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-tag___bvVWv_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag--with-hover___OE7lc_990311c:hover{background-color:var(--mdc-color-palette-electric-blue);box-shadow:var(--mdc-elevation-8);color:var(--mdc-color-neutral-white);cursor:pointer}.mdc-c-tag--with-hover___OE7lc_990311c:focus-visible{border:var(--mdc-size-border-width-1) solid var(--mdc-color-palette-electric-blue);outline:var(--mdc-size-border-width-4) solid #2155ff66}.mdc-c-tag--checked___BnJWp_990311c{background-color:var(--mdc-color-neutral-gray-70);color:var(--mdc-color-neutral-white)}</style><style type=\"text/css\">.mdc-c-select-custom___TOhaq_990311c{max-width:100%;position:relative}.mdc-c-select-custom--fit-content-width___epwhR_990311c{width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-select-custom__select-button___5fnAN_990311c{background-color:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);color:var(--mdc-color-neutral-black);cursor:pointer;grid-auto-flow:column;justify-content:space-between;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-8) var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);transition:all .12s linear}.mdc-c-select-custom__select-button--expanded___eNvKm_990311c{background-color:var(--mdc-color-palette-electric-blue);border:0;color:var(--mdc-color-neutral-white)}.mdc-c-select-custom__label___8vCRC_990311c{text-wrap:nowrap;overflow:hidden;text-overflow:ellipsis}.mdc-c-select-custom__list___xXyVs_990311c{background-color:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-8);margin:0;max-width:90vw;min-width:100%;padding:0;position:absolute;width:-webkit-max-content;width:max-content;z-index:1}.mdc-c-select-custom__list--collapsed___jyYdT_990311c{display:none}.mdc-c-select-custom__list--right___SwAN0_990311c{right:0}@media (min-width:768px){.mdc-c-select-custom__list___xXyVs_990311c{max-width:max(50vw,100%)}}.mdc-c-select-custom__list-item___7DeLO_990311c{cursor:pointer;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16)}.mdc-c-select-custom__list-item___7DeLO_990311c:focus,.mdc-c-select-custom__list-item___7DeLO_990311c:hover{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-select-custom__list-item--select-all___7U9Az_990311c{border-bottom:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-10)}.mdc-c-select-custom__footer___dMcSY_990311c{box-shadow:var(--mdc-elevation-8);padding:var(--mdc-size-spacing-16)}.mdc-c-select-custom___TOhaq_990311c [class^=mdc-c-button]{min-width:-webkit-fit-content;min-width:-moz-fit-content;min-width:fit-content}</style><style type=\"text/css\">.mdc-c-datepicker___706mw_990311c{color:var(--mdc-color-neutral-gray-80);position:relative}.mdc-c-datepicker__input___-ZW4z_990311c{padding-right:var(--mdc-size-spacing-32)!important}.mdc-c-datepicker__popper___AOPhF_990311c{background-color:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-4);font-family:var(--mdc-font-family-default-primary);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-24);z-index:var(--mdc-zindex-10)}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper-header___9HTov_990311c{align-items:center;display:flex;justify-content:space-between}.mdc-c-datepicker__popper-header___9HTov_990311c button{background:none;border:0;cursor:pointer;height:var(--mdc-size-spacing-40);outline:none;width:var(--mdc-size-spacing-40)}.mdc-c-datepicker__popper-header___9HTov_990311c button:hover{background-color:var(--mdc-color-neutral-gray-06);border-radius:50%}.mdc-c-datepicker__popper-year-nav___sRMUD_990311c{align-items:center;display:flex;flex:1;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-medium);gap:var(--mdc-size-spacing-8);justify-content:center;line-height:var(--mdc-size-line-height-24)}.mdc-c-datepicker__popper-year-nav___sRMUD_990311c select{border:none;cursor:pointer;outline:none;padding:0 var(--mdc-size-spacing-32) 0 0;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-datepicker__year-select___YPSz2_990311c{align-self:normal}.mdc-c-datepicker__reset-btn___tdJ-r_990311c{margin-right:var(--mdc-size-spacing-32)}.mdc-c-datepicker___706mw_990311c .react-datepicker__calendar-icon{color:var(--mdc-color-neutral-gray-80);cursor:pointer;position:absolute;right:var(--mdc-size-spacing-16);top:var(--mdc-size-spacing-8)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day-names{display:flex;font-size:var(--mdc-size-font-14);font-weight:var(--mdc-font-weight-medium);line-height:var(--mdc-size-line-height-20)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day,.mdc-c-datepicker___706mw_990311c .react-datepicker__day-name{height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-spacing-40);outline:none;text-align:center;width:var(--mdc-size-spacing-40)}.mdc-c-datepicker___706mw_990311c .react-datepicker__month{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-datepicker___706mw_990311c .react-datepicker__week{display:flex}.mdc-c-datepicker___706mw_990311c .react-datepicker__day{cursor:pointer}.mdc-c-datepicker___706mw_990311c .react-datepicker__day:hover{background-color:var(--mdc-color-neutral-gray-10)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--outside-month{color:var(--mdc-color-neutral-gray-30)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--today{border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-80);font-weight:var(--mdc-font-weight-bold)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--in-range,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--in-selecting-range{background-color:var(--mdc-color-status-light-blue)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--range-end,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--selected{background-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-neutral-white);font-weight:var(--mdc-font-weight-bold)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--range-end:hover,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--selected:hover{background-color:var(--mdc-color-status-dark-blue)}.mdc-c-datepicker___706mw_990311c .react-datepicker__today-button{display:flex;justify-content:space-between;padding-top:var(--mdc-size-spacing-8);width:100%}.mdc-c-datepicker___706mw_990311c .react-datepicker__aria-live{border:0;-webkit-clip-path:circle(0);clip-path:circle(0);height:0;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:0}</style><style type=\"text/css\">.mdc-c-modal__backdrop___-KX-s_990311c{align-items:center;animation-duration:.4s;animation-name:animatetop___aWqMX_990311c;background-color:#000c;inset:0;justify-content:center;overflow:auto;position:fixed;z-index:var(--mdc-zindex-20)}.mdc-c-modal__backdrop--bottom___le1-H_990311c{animation-name:animatebottom___4ILUZ_990311c}.mdc-c-modal__backdrop--hide___LW7W8_990311c{opacity:0}@keyframes animatetop___aWqMX_990311c{0%{opacity:0;top:-300px}to{opacity:1;top:0}}@keyframes animatebottom___4ILUZ_990311c{0%{bottom:-300px;opacity:0}to{bottom:0;opacity:1}}.mdc-c-modal__content___os-1D_990311c{box-sizing:border-box;margin:96px auto auto;max-width:624px;padding:var(--mdc-size-spacing-64);position:relative;width:100%}@media (max-width:1179px){.mdc-c-modal__content___os-1D_990311c{margin-top:var(--mdc-size-spacing-80)}}@media (max-width:767px){.mdc-c-modal__content___os-1D_990311c{margin:0;max-width:100%;min-height:100%;padding:var(--mdc-size-spacing-40)}}.mdc-c-modal__content--align-top___BfmM5_990311c{margin-top:0}.mdc-c-modal__content--align-bottom___-T7nI_990311c{animation-name:animatebottom___4ILUZ_990311c;bottom:0;position:absolute}.mdc-c-modal__content--full-width___hDjtB_990311c{max-width:100%}.mdc-c-modal__content--spacing-compact___5fP7H_990311c{padding:var(--mdc-size-spacing-40)}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__close-button___ZYOFu_990311c{position:absolute;right:var(--mdc-size-spacing-8);top:var(--mdc-size-spacing-8)}@media (min-width:768px){.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__close-button___ZYOFu_990311c{right:var(--mdc-size-spacing-16);top:var(--mdc-size-spacing-16)}}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__header___Fts7-_990311c{margin-bottom:var(--mdc-size-spacing-32)}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__header___Fts7-_990311c p{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28)}</style><style type=\"text/css\">:root .mdc-c-tabs___7eVdv_990311c,[data-module-theme=light] .mdc-c-tabs___7eVdv_990311c{--paddle-bg-right:linear-gradient(to right,#0000,var(--mdc-color-neutral-white) 50%);--paddle-bg-left:linear-gradient(to left,#0000,var(--mdc-color-neutral-white) 50%)}[data-module-theme=dark] .mdc-c-tabs___7eVdv_990311c{--paddle-bg-right:linear-gradient(to right,#0000,var(--mdc-color-palette-deep-blue) 50%);--paddle-bg-left:linear-gradient(to left,#0000,var(--mdc-color-palette-deep-blue) 50%)}.mdc-c-tabs___7eVdv_990311c{position:relative}.mdc-c-tabs__tablist-wrapper___dBa0k_990311c{overflow-x:scroll}.mdc-c-tabs__tablist-wrapper___dBa0k_990311c::-webkit-scrollbar{height:0;width:0}.mdc-c-tabs__tablist___I130n_990311c{grid-gap:var(--mdc-size-spacing-24);display:grid;grid-auto-flow:column;justify-content:start;margin:0;margin-bottom:calc(var(--mdc-size-border-width-1)*-1);padding:0;width:-webkit-max-content;width:max-content}.mdc-c-tabs__tablist--centered___UQ0o8_990311c{justify-content:center}.mdc-c-tabs__tab___IXSdl_990311c{border:0;border-bottom:var(--mdc-size-border-width-4) solid #0000;display:block;font-family:var(--mdc-font-family-default-primary);font-weight:var(--mdc-font-weight-light);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-4);width:-webkit-max-content;width:max-content}.mdc-c-tabs__tab___IXSdl_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab--is-active___G72D-_990311c{border-bottom-color:var(--button-minimal-tertiary-hover)}.mdc-c-tabs__tabpanel___chsU7_990311c{border-top:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-18);padding:var(--mdc-size-spacing-16) 0}.mdc-c-tabs__paddles___msvdU_990311c .mdc-c-tabs__paddle___Y09Ta_990311c{background-image:var(--paddle-bg-left);border:0;min-width:var(--mdc-size-spacing-16);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-24) var(--mdc-size-spacing-16) var(--mdc-size-spacing-8);position:absolute;top:0}.mdc-c-tabs__paddles___msvdU_990311c .mdc-c-tabs__paddle--right___KtnNh_990311c{background-image:var(--paddle-bg-right);padding-left:var(--mdc-size-spacing-24);padding-right:var(--mdc-size-spacing-8);right:0}.mdc-c-tabs__paddle___Y09Ta_990311c:focus,.mdc-c-tabs__tab___IXSdl_990311c:focus{outline:none}.mdc-c-tabs__paddle___Y09Ta_990311c:focus-visible,.mdc-c-tabs__tab___IXSdl_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default);outline-offset:calc(var(--mdc-size-border-width-4)*-1)}</style><style type=\"text/css\">.mdc-c-typeahead___31M3S_990311c{position:relative}.mdc-c-typeahead__menu___kINRW_990311c{background-color:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-30);box-shadow:var(--mdc-elevation-2);margin-top:var(--mdc-size-spacing-4);padding:0;width:100%;z-index:1}.mdc-c-typeahead__menu___kINRW_990311c ul{list-style:none;margin:0;padding:0}.mdc-c-typeahead__menu___kINRW_990311c ul li{cursor:pointer;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16)}.mdc-c-typeahead__menu-item--active___q5GP9_990311c{background-color:var(--mdc-color-neutral-gray-03);outline:none}</style><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/08dfc05290ce60e1.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-3464\" src=\"/_next/static/chunks/3464.caabbe0cce2df796.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-2453\" src=\"/_next/static/chunks/2453.5bbec710ffd42462.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/7f0894b6dca7827f.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-2169\" src=\"/_next/static/chunks/2169.db1ed0d7c6e757b7.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/46b1c7e4e497c465.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-5317\" src=\"/_next/static/chunks/5317.7ad5e77119c7b9d7.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-9484\" src=\"/_next/static/chunks/9484.64b6a3050886e09e.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/8cd0628f2230b764.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-6957\" src=\"/_next/static/chunks/6957.260f832111970a25.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-895\" src=\"/_next/static/chunks/895.63b261a2b180ec79.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-7044\" src=\"/_next/static/chunks/7044.d5c57fbc84841f29.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-906\" src=\"/_next/static/chunks/906.033c0adf90096a05.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-9829\" src=\"/_next/static/chunks/9829.1c1a2c713fe60a17.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/d4aec97cc669860d.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-3305\" src=\"/_next/static/chunks/3305.922e1efcae077965.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/5c2a9bc874cbce83.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-1649\" src=\"/_next/static/chunks/1649.100f3837f09cbcf8.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-1230\" src=\"/_next/static/chunks/1230.de91f4807c3ee7d1.js\"></script></head><body style=\"\"><div id=\"__next\" data-reactroot=\"\"><div class=\"Layout_mck-c-skipbar__K684J\"><a data-component=\"mdc-c-link\" href=\"#skipToMain\" class=\"mdc-c-button___U4iY2_990311c mdc-c-button--primary___Ed-lT_990311c mdc-c-button--size-medium\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Skip to main content</span></a></div><main class=\"mck-o-container--outer\" data-layer-region=\"body\" role=\"main\" id=\"skipToMain\"><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"dark\" data-module-background=\"deep-blue\" data-module-category=\"\" data-module-gradient-position=\"bottom-right\" class=\"mck-o-edge-to-edge FiftyFiftyHero_mck-c-fifty-fifty-hero__wrapper__74aGq\"><div><div class=\"mck-o-container\"><div class=\"mck-o-container--wrapped mdc-u-grid\"><div class=\"FiftyFiftyHero_mck-c-fifty-fifty-hero__dI9Yx\"><style>\n    .background-image-fifty-fifty-hero-undefined {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/accelerating-clinical-trials-hero-1536x864.jpg?cq=50&mw=767&car=4:3&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          @media screen and (min-width: 768px){\n            \n    .background-image-fifty-fifty-hero-undefined {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/accelerating-clinical-trials-hero-1536x864.jpg?cq=50&mw=1536&car=16:9&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          }\n        </style><div data-component=\"mdc-c-background-image\" class=\"mdc-c-bg-image___GJdv1_990311c background-image-fifty-fifty-hero-undefined FiftyFiftyHero_mck-c-fifty-fifty-hero__media__TroHX FiftyFiftyHero_mck-c-fifty-fifty-hero__media--absolute__YlXtV\"></div><div class=\"FiftyFiftyHero_mck-c-fifty-fifty-hero__wrapper-text__13v1d FiftyFiftyHero_mck-c-fifty-fifty-hero__wrapper-text--default-style__TJLUl mdc-u-spaced-mobile\"><div class=\"mdc-u-grid\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c\"><h1 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-2\"><div>Accelerating clinical trials to improve biopharma R&amp;D productivity</div></h1><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-10\"><div class=\"mck-u-links-inline mck-c-generic-item__description\"><time datetime=\"2024-01-22T00:00:00Z\">January 22, 2024</time> | Article</div></div></div></div></div></div></div></div></div></div></div></div><div class=\"mck-o-container\"><div class=\"mck-o-container--wrapped mck-o-container--mobile-spacing mdc-u-grid mdc-u-grid-gutter-xxl\"><section data-layer-region=\"article-body-header\" class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-animation-blur-in-400 byline-share-container\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-7 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-8 mdc-u-ts-10\"></div></section><section class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-animation-blur-in-400\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-5\"><div class=\"mck-u-links-inline\">Biopharma sponsors are seeking to accelerate clinical trials and reduce costs through a set of targeted actions aimed at improving patient and site engagement and enrollment productivity.</div></div></div></section><main data-layer-region=\"article-body\" class=\"mdc-u-grid mdc-u-grid-gutter-xxl\"><div class=\"mdc-u-grid mdc-u-grid-col-1 mdc-u-grid-col-md-12\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><div class=\"mdc-o-content-body mck-u-dropcap\">\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"DownloadsSidebar_mck-c-downloads-sidebar__iFmyt mck-o-xs-right-span\"><div data-layer-region=\"downloads-right-rail\"><h3 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c\">DOWNLOADS</h3><div><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c\"><a data-component=\"mdc-c-link\" href=\"#/download/%2F~%2Fmedia%2Fmckinsey%2Findustries%2Flife%20sciences%2Four%20insights%2Faccelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity%2Faccelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity.pdf%3FshouldIndex%3Dfalse\" class=\"DownloadsSidebar_mck-c-downloads-sidebar__download-link__fPqFQ mdc-c-link___lBbY1_990311c\" target=\"_self\" data-layer-event-prefix=\"Download Link\" data-layer-action=\"click\" data-layer-report-type=\"Article\" data-layer-file-name=\"accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\" data-layer-report-name=\"accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity>Article\"><span data-component=\"mdc-c-icon\" class=\"mdc-c-icon___oi7ef_990311c mdc-c-icon--size-md___yi5fA_990311c mck-download-icon\"></span><span class=\"mdc-c-link__label___Pfqtd_990311c\">Article (10 pages)</span></a></div></div></div></div>\n<p><strong>Biopharmaceutical (biopharma) R&amp;D</strong> stands at an inflection point, with the limiting factor for innovation no longer science or funding but the speed at which clinical trials can be completed because of a shortage of study participants and clinical site professionals such as principal investigators (PIs), site coordinators, and nurses.</p>\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"light\" data-module-background=\"lightest-grey\" data-module-category=\"\" data-module-gradient-position=\"bottom-right\" class=\"mck-c-inline-module-container SideBar_mck-c-sidebar__bgimg-wrapper__Qj4Dt mck-o-sm-left-span SideBar_mck-c-sidebar__sidebar-wrapper__Dpjw2 SideBar_mck-c-sidebar__sidebar-wrapper--istablet__IQ6ii mck-u-screen-only mck-c-module-wrapper\" data-layer-region=\"sidebar\"><div class=\"SideBar_mck-c-sidebar__epoAm  mck-o-md-center\"><div class=\"SideBar_mck-c-sidebar__share-icons-wrapper__9gB_c\"><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c mdc-c-link-container--display-column___X0HDD_990311c SideBar_mck-c-sidebar__share-icons___eQy6\"><button data-component=\"mdc-c-button\" aria-label=\"Expandable Sidebar\" type=\"button\" id=\"button_id\" class=\"mdc-c-button___U4iY2_990311c mdc-c-button--ghost mdc-c-button--size-medium SideBar_mck-c-sidebar__toggle-btn__EL8iE\" aria-expanded=\"false\" data-layer-event-prefix=\"UI Item\" data-layer-action=\"click\" data-layer-category=\"sidebar\" data-layer-subcategory=\"open\" data-layer-text=\"open sidebar\"><span data-component=\"mdc-c-icon\" class=\"mdc-c-icon___oi7ef_990311c mdc-c-icon--radial___y3csX_990311c mdc-c-icon--size-xxl___cL3ZT_990311c mck-plus-no-circle-icon\"></span></button></div></div><div class=\"SideBar_mck-c-sidebar__content-outer__UdWCq\"><div class=\"SideBar_mck-c-sidebar__eyebrow__5GSEq\">Sidebar</div><div class=\"SideBar_mck-c-sidebar__content__raEwe\"><h2 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-3 SideBar_mck-c-sidebar__content-heading__NJekY\"><div>About the authors</div></h2><div class=\"SideBar_mck-c-sidebar__content-description__4p9iI mdc-u-ts-7\"><div class=\"mdc-o-content-body\"><p>This article is a collaborative effort by <a href=\"/our-people/gaurav-agrawal\">Gaurav Agrawal</a>, Jacob Kautzky, <a href=\"/our-people/harriet-keane\">Harriet Keane</a>, <a href=\"/our-people/brandon-parry\">Brandon Parry</a>, <a href=\"/our-people/valentina-sartori\">Valentina Sartori</a>, and Amy Silverstein, representing views from McKinseys Life Sciences Practice.</p></div></div></div></div></div></div>\n<p>In this environment, the most successful clinical trial sponsors (that is, biopharma manufacturers that are responsible for trial initiation, management, and financing) will be the biopharma companies that evolve their clinical trial delivery model to create a compelling value proposition for study participants and sites. This article explores the barriers to improving R&amp;D productivity, including long clinical trial timelines and challenges to clinical trial recruitment, and actions sponsors can take to increase trial participants and improve the experience of clinical trial sites.</p>\n<h2>A golden era for biopharma innovation</h2>\n<!-- -->\n<p>Today, the biopharma industry has its largest and most diverse clinical pipeline in history, the culmination of decades of innovative research. The total number of distinct drugs in development grew from 3,200 in 2012 to 6,100 in 2022.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"fe8fe279-df77-4186-8a74-4ed28b2207c9\"><sup class=\"FootNote_footnotesup__e73z_\">1</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"fe8fe279-df77-4186-8a74-4ed28b2207c9\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Based on McKinsey analysis of PharmaProjects data 2022.</span></span></span></a></span> Furthermore, this pipeline is increasingly diverse; 14 percent of assets use modalities validated over the past five years (predominantly various forms of cell and gene therapy).<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"da0d707a-2c54-4b97-9585-579050e58035\"><sup class=\"FootNote_footnotesup__e73z_\">2</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"da0d707a-2c54-4b97-9585-579050e58035\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Based on McKinsey analysis of PharmaProjects data 2022.</span></span></span></a></span></p>\n<p>The ability to deliver on this expansive pipeline has been enabled by government investmentincluding an estimated $18 billion made available for Operation Warp Speed and $48 billion invested each year by the National Institutes of Health alone<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"d53e12a0-7902-4ded-9068-e4994fb558c7\"><sup class=\"FootNote_footnotesup__e73z_\">3</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"d53e12a0-7902-4ded-9068-e4994fb558c7\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Operation Warp Speed: Implications for global vaccine security, <em>The Lancet Global Health</em>, March 26, 2021; Budget, National Institutes of Health, reviewed October 24, 2023.</span></span></span></a></span>and private markets, with an estimated $146 billion in life sciences venture capital funding in the past three years.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"8ca289d8-885e-4722-868e-87ba97f84f10\"><sup class=\"FootNote_footnotesup__e73z_\">4</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"8ca289d8-885e-4722-868e-87ba97f84f10\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">McKinsey analysis of BioCentury Inc., accessed February 2023.</span></span></span></a></span></p>\n<h2>Low R&amp;D productivity driven by lengthy clinical trial timelines and increasing trial costs</h2>\n<p>Although the current climate for biopharma innovation is seemingly ideal, with 4,300 clinical trials starting in 2022 alone, R&amp;D productivity remains stubbornly low. From 2012 to 2022, inflation-adjusted industry R&amp;D spending increased 44 percent, from about $170 billion to $247 billion, (Exhibit 1).<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"92021b0f-d887-4cf4-bbb0-c637350e36ac\"><sup class=\"FootNote_footnotesup__e73z_\">5</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"92021b0f-d887-4cf4-bbb0-c637350e36ac\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Based on McKinsey analysis of data from Pharmaprojects, 2022 and Evaluate Pharma, August 2023.</span></span></span></a></span> However, the number of US novel drug approvals remains flat at an average of 43 per year, meaning the attrition-adjusted cost to develop a single novel asset is now estimated to be as high as $2.8 billion.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"5dd6fbdf-a574-4c4b-be1d-02c627f777a9\"><sup class=\"FootNote_footnotesup__e73z_\">6</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"5dd6fbdf-a574-4c4b-be1d-02c627f777a9\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">CDERs annual novel drug approvals: 2013  2022, New Drug Therapy Approvals 2022, U.S. Food &amp; Drug Administration, current as of January 10, 2023.</span></span></span></a></span></p>\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 1</span></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex1-v3.svgz?cq=50&amp;cpy=Center\"><img alt=\"Inflation-adjusted pharma R&amp;D spending has outpaced clinical trial starts, with no corresponding improvement in technical and regulatory success.\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex1-v3.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div>\n<p>Multiple factors underlie low R&amp;D productivity, including consistently low success rates; only about 13 percent of assets that enter the Phase 1 trial stage go on to launch.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"b8e1e6fb-724a-4586-816e-719dcd26c250\"><sup class=\"FootNote_footnotesup__e73z_\">7</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"b8e1e6fb-724a-4586-816e-719dcd26c250\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">McKinsey analysis.</span></span></span></a></span> In addition, development costs remain high (accounting for as much as 60 to 70 percent of total costs)<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"2379ec60-34f5-4c0d-9f31-ebccb3e67c63\"><sup class=\"FootNote_footnotesup__e73z_\">8</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"2379ec60-34f5-4c0d-9f31-ebccb3e67c63\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">2022 PhRMA Annual Membership Survey, PhRMA.</span></span></span></a></span> and development cycles are long (taking an average of 12 years to develop a novel medicine).<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"079afa90-d85b-4432-915f-df7480e50c4c\"><sup class=\"FootNote_footnotesup__e73z_\">9</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"079afa90-d85b-4432-915f-df7480e50c4c\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Gaurav Agrawal, Felix Bader, Jan Gnthner, and Stephan Wurzer, <a href=\"/industries/life-sciences/our-insights/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\">Fast to first-in-human: Getting new medicines to patients more quickly</a>, McKinsey, February 10, 2023.</span></span></span></a></span> Furthermore, development timelines have extended. For example, according to McKinsey analysis, between the periods of 2011 to 2015 and 2016 to 2021, the average clinical trial lengthened from 41 to 44 months for Phase 3 trials and from 37 to 41 months for Phase 2 trials.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"df479cd8-9a03-421e-bc1a-68c1d072ed93\"><sup class=\"FootNote_footnotesup__e73z_\">10</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"df479cd8-9a03-421e-bc1a-68c1d072ed93\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Protocol design scope and execution burden continue to rise, most notably in Phase III, <em>Tufts CFSD Impact report</em>, May/June 2023, Volume 25, Number 3; Jason Scott, Phase 3 trials significantly rising in complexity, says CSDD, CenterWatch, May 15, 2023.</span></span></span></a></span> Today, it is estimated that up to 80 percent of clinical trials fail to finish on time.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"9416008d-677a-48cb-b3f5-9f4caacd5194\"><sup class=\"FootNote_footnotesup__e73z_\">11</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"9416008d-677a-48cb-b3f5-9f4caacd5194\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Mette Brgger-Mikkelsen et al., Online patient recruitment in clinical trials: Systematic review and meta-analysis, <em>Journal of Medical Internet Research</em>, November 2020.</span></span></span></a></span> At the same time, speed of clinical development is critical for biopharma companies and patients. For companies, the rise in herding, in which multiple companies focus on the same high-potential mechanisms of action (MoAs), increases the pressure to be first to market. Over the past 20 years, the top five most active MoAs in a given year saw an almost fivefold increase in the number of assets being developed, with the first product to market achieving outsize success.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"4c9426c1-4630-45bb-ba08-d79c46423c91\"><sup class=\"FootNote_footnotesup__e73z_\">12</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"4c9426c1-4630-45bb-ba08-d79c46423c91\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Christian Fougner et al., Herding in the drug development pipeline, <em>Nature Reviews Drug Discovery</em>, April 28, 2023, Volume 22.</span></span></span></a></span> Furthermore, the passage of the US Inflation Reduction Act, which includes provisions to reduce drug prices, will influence which indications companies pursue and increase the importance of being first to market.</p>\n<p>For patients with many indications, unmet need remains acute; more than 6,000 rare diseases have no known therapy,<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"15f42e7a-fbb4-42bf-aad6-f7b48157064b\"><sup class=\"FootNote_footnotesup__e73z_\">13</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"15f42e7a-fbb4-42bf-aad6-f7b48157064b\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">McKinsey analysis of Orphanet.</span></span></span></a></span> and numerous cancers (for example, pancreatic cancers, mesotheliomas, and brain cancers) have a five-year survival rate of less than 35 percent.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"07c307b5-2cd2-41c2-889d-ba966859ca77\"><sup class=\"FootNote_footnotesup__e73z_\">14</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"07c307b5-2cd2-41c2-889d-ba966859ca77\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Cancer stat facts: Pancreatic cancer, Surveillance, Epidemiology, and End Results Program (SEER), National Cancer Institute, accessed November 2023; Survival rates for malignant mesothelioma, American Cancer Society, last revised March 2, 2023; Cancer stat facts: Brain and other nervous system cancer, SEER, National Cancer Institute, accessed November 2023.</span></span></span></a></span> For a pharma company with three to five investigational drugs entering first in human studies each year, a 12-month development acceleration applied across the portfolio can translate to more than $400 million in net present value for the sponsor and deliver incalculable benefits for patients and their families.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"7e6b1112-b47b-4a05-8523-45941585d7fb\"><sup class=\"FootNote_footnotesup__e73z_\">15</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"7e6b1112-b47b-4a05-8523-45941585d7fb\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Gaurav Agrawal, Felix Bader, Jan Gnthner, and Stephan Wurzer, <a href=\"/industries/life-sciences/our-insights/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\">Fast to first-in-human: Getting new medicines to patients more quickly</a>, McKinsey, February 10, 2023.</span></span></span></a></span></p>\n<h2>Challenges in recruitment for clinical trials</h2>\n<p>Although there are multiple levers to pull to improve R&amp;D productivity, development acceleration is one R&amp;D leaders can explore immediately and one that can have a greater impact on patients. In clinical trials, treatment durations are often fixed, and study start-up and close-out account for only a small portion of overall trial duration (with best-in-class timelines of about two months and one month, respectively).</p>\n<p>Therefore, the biggest opportunity for sponsors to accelerate clinical trials is to increase the speed    and improve the efficiency of clinical trial enrollment; however, participant recruitment is increasingly difficult. For example, the rate of clinical trial participants enrolled per site per month in oncology and nononcology Phase 3 trials declined by 14 percent and 54 percent, respectively, in the periods 2012 to 2014 and 2021 to 2023 (Exhibit 2).</p>\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 2</span></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex2-v3.svgz?cq=50&amp;cpy=Center\"><img alt=\"Industry enrollment productivity for Phase 3 regulatory trials has declined, with sites enrolling fewer patients per month and per site.\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex2-v3.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div>\n<p>Factors contributing to enrollment challenges exist on both the sponsor and site side of the equation. Sponsors require more participants than ever and are defining eligibility more specifically. Meanwhile, more complex protocols have increased the demands placed on sites at a time when clinical trial site staff turnover (PIs, clinical trial coordinators, and nurses) is at an all-time high,<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"c19f79aa-bf33-452c-b45f-2b7c5141380f\"><sup class=\"FootNote_footnotesup__e73z_\">16</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"c19f79aa-bf33-452c-b45f-2b7c5141380f\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Grace Sun et al., Crisis of the clinical trials staff attrition after the COVID-19 pandemic, <em>JCO Oncology Practice</em>, August 1, 2023, Volume 19, Number 8.</span></span></span></a></span> and physicians are less motivated to participate in clinical research because of changes to incentive models.</p>\n<h3>Increasing demand for trial participants</h3>\n<p>According to McKinsey analysis, over the past decade demand for trial participants has increased almost 10 percent as a result of more and larger trials; comparing 2019 to 2022, the total target enrollment of trials starting in those years grew 18 percent, from 2.2 million to 2.6 million (Exhibit 3).</p>\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 3</span></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex3-v3.svgz?cq=50&amp;cpy=Center\"><img alt=\"Demand for clinical trial patients grew by about 10 percent between 2012 and 2022.\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex3-v3.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div>\n<p>Moreover, demand is spread unevenly, with disproportionately high trial volumes compared to overall incidence for some indications (for instance, multiple myeloma, cystic fibrosis, multiple sclerosis, non-Hodgkin lymphoma, and thalassemia).</p>\n<p>Oncology poses a particular challenge; the number of required participants has increased from about 1.1 million in 2019 to about 1.3 million in 2022.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"d99b8776-a7a4-471a-99dd-76f30913c75f\"><sup class=\"FootNote_footnotesup__e73z_\">17</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"d99b8776-a7a4-471a-99dd-76f30913c75f\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Based on McKinsey analysis including all trials currently recruiting for breast cancer, cervical cancer, CRC, leukemia, melanoma, multiple myeloma, NHL, NSCLC, prostate cancer, and renal cell carcinoma.</span></span></span></a></span> (As a point of comparison, an estimated 1.9 million individuals were diagnosed with cancer in the United States in 2022.)<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"d1ca7d7b-55ac-4ea9-8682-c8816604d6a9\"><sup class=\"FootNote_footnotesup__e73z_\">18</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"d1ca7d7b-55ac-4ea9-8682-c8816604d6a9\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs, and Ahmedin Jemal, Cancer statistics, 2022, <em>CA: A Cancer Journal for Clinicians</em>, January 12, 2022.</span></span></span></a></span> Despite this considerable clinical research activity, only about 6 percent of US cancer patients are estimated to participate in a clinical trial. This participation rate is only 4 percent for patients receiving care at nonNational Cancer Institute (NCI) centers compared to 19 percent at NCI centers.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"b9f262e1-b8cf-4b5e-a062-706eb889dc2f\"><sup class=\"FootNote_footnotesup__e73z_\">19</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"b9f262e1-b8cf-4b5e-a062-706eb889dc2f\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Joseph M. Unger and Mark Fleury, Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer, <em>Journal of Clinical Oncology</em>, September 2021, Volume 39.</span></span></span></a></span> These trends in concentration of care are applicable across the world, including in other geographies where clinical trials are commonly run (for example, Eastern Europe and Western Europe).</p>\n<p>The enrollment challenge is further exacerbated by an increased focus on precision medicine, whereby study groups are tightly defined with the goal of developing medicines that are highly effective in subsets of participants.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"0d8bf75e-326a-459c-b0b1-0942f5776000\"><sup class=\"FootNote_footnotesup__e73z_\">20</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"0d8bf75e-326a-459c-b0b1-0942f5776000\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Christian Fougner et al., Herding in the drug development pipeline, <em>Nature Reviews Drug Discovery</em>, April 28, 2023, Volume 22.</span></span></span></a></span> For example, as of 2022, more than half of oncology trials are estimated to have a biomarker-defined target subpopulation.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"356d6c7d-c07e-48ac-ae90-0278d4e4ca77\"><sup class=\"FootNote_footnotesup__e73z_\">21</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"356d6c7d-c07e-48ac-ae90-0278d4e4ca77\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Jurgita Gammall and Alvina G. Lai, Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review, <em>npj Precision Oncology</em>, April 20, 2022.</span></span></span></a></span> This is the case even with indications traditionally viewed as homogenous, such as lung cancer, which has more than ten subpopulations being investigated in clinical trials.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"3699367c-4474-448d-9309-605b74a9966e\"><sup class=\"FootNote_footnotesup__e73z_\">22</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"3699367c-4474-448d-9309-605b74a9966e\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Shenduo Li et al., Emerging targeted therapies in advanced non-small-cell lung cancer, <em>Cancers (Basel)</em>, June 2023, Volume 15, Number 11, Epidermal Growth Factor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene encoding a type I (ROS1), proto-oncogene B-Raf (BRAF), Neurotrophic tyrosine receptor kinase (NTRK), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 (HER-2), and Programmed Cell Death Ligand 1 (PD-L1).</span></span></span></a></span></p>\n<p>These industry-wide dynamics have made recruiting increasingly challenging. Whereas a site may have only a handful of (or zero) eligible participants for a given study, the time and financial burden of standing up a clinical trial at even a single site is undiminished for sponsor and site.</p>\n<h3>Rising burden on sites</h3>\n<p>As sponsors strive to generate more compelling data packages for regulators and internal translational research (to inform the next generation of drug discovery), the burden on sites has continued to rise. As a measure of trial complexity, the average number of Phase 2 and Phase 3 endpoints (specifically desired measurements of clinical trial outcomes) has increased from 17 in the period from 2013 to 2016 to about 21 in the period from 2017 to 2020,<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"a4819ac9-9e72-4f21-b70d-e99e507b112c\"><sup class=\"FootNote_footnotesup__e73z_\">23</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"a4819ac9-9e72-4f21-b70d-e99e507b112c\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Trials, <em>Tufts CFSD Impact report</em>, May/June 2021, Volume 23, Number 3; see also Charlie Passut, Trial complexity, endpoints continue to increase, stretching site resources, CenterWatch, January 18, 2021.</span></span></span></a></span> with many endpoints requiring specific equipment or training at the site level. Furthermore, although growing adoption of eClinical technologies theoretically reduces dependence on paper forms, sites typically need to implement or integrate five or more systemsincluding electronic data capture, electronic clinical outcome assessments, and electronic consent formsbefore they can start to recruit study participants.</p>\n<h3>Challenging physician incentives</h3>\n<p>The United States continues to remain an important geography for clinical trials, with more than 83 percent of global Phase 3 industry-sponsored trials having at least one US site.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"5164372e-53e5-4c12-a0c7-54629e1e35e0\"><sup class=\"FootNote_footnotesup__e73z_\">24</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"5164372e-53e5-4c12-a0c7-54629e1e35e0\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Clinicaltrials.gov; McKinsey analysis including all global, non-infectious disease Phase 3 trials completed between 2012 and 2023, with global trials defined as occurring in at least three countries.</span></span></span></a></span> While all physicians are determined to deliver the best possible care, current incentive models can make participation in clinical trials challenging. For example, in the United States, most physicians are assessed by Centers for Medicare and Medicaid Services (CMS) using a model based on Relative Value Units, which puts a low premium on clinical research activity. Furthermore, at a provider level, income from clinical research patient visits is often marginal in terms of overall revenue versus traditional standard-of-care visits.</p>\n<p>Global turnover of healthcare staff (including PIs, trial coordinators, and nurses) is at an all-time high; an estimated 50 percent of clinical trial PIs participated in only one clinical trial between 1999 and 2015, a trend that predates the Great Resignation of the past few years.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"be7b636f-bfe8-48fe-85c1-7e97a10ffedb\"><sup class=\"FootNote_footnotesup__e73z_\">25</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"be7b636f-bfe8-48fe-85c1-7e97a10ffedb\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Christopher B. Fordyce et al., Trends in clinical trial investigator workforce and turnover: An analysis of the U.S. FDA 1572 BMIS database, Contemporary Clinical Trials Communications, 2019, Volume 15.</span></span></span></a></span> All of this contributes to the fact that more than two-thirds of global PIs remain one and done clinical trial investigatorsa persistent trend over the past decade.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"656dd5c6-851f-4db3-9da8-5f19c1dd0429\"><sup class=\"FootNote_footnotesup__e73z_\">26</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"656dd5c6-851f-4db3-9da8-5f19c1dd0429\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Ken Gatz, Tracking change in the global investigative site landscape, <em>Applied Clinical Trials</em>, December 2021, Volume 30, Number 12; James Miessler, Unprecedented decline in one-and-done PI rate leads to reversal of turnover trend, CenterWatch, January 10, 2022.</span></span></span></a></span></p>\n<h2>Five opportunities to accelerate recruitment to boost overall R&amp;D productivity</h2>\n<p>Although addressing challenges of physician burnout and misaligned incentive models may be beyond the scope of most sponsors, the biopharma industry can take meaningful action to accelerate clinical trial recruitment. Sponsors can explore five areas in particular to answer this question: What would it take to make trial sizes 20 percent smaller than five years ago, cut recruitment timelines in half, and keep costs the same?</p>\n<h3>1. Apply innovative trial designs to reduce total required study participants</h3>\n<p>Minimizing the number of participants exposed to experimental therapies is a common goal of regulators and sponsors. Increased use of statistical innovation and predictive modelingto optimize the number of clinical trial experimental groups and better estimate trial size to avoid statistical overpoweringcan effectively help achieve this goal. Likewise, although not yet widespread, use of real-world evidence (such as borrowed algorithms) to supplement participants data has significant potential to reduce the number of required participants by enriching control arms (control patients) while not going as far as full synthetic controls (controls created using real-world data rather than actual enrollees). Additionally, sponsors continue to expand the use cases for innovative trial design beyond oncology. This includes umbrella studies to investigate multiple therapies in a single study (with the possibility to add arms as standard of care evolves), Bayesian clinical trials to reduce the number of clinical trial participants over the length of the study, and basket or multi-indication trials to more efficiently test novel therapies.</p>\n<h3>2. Differentiate with simpler, patient-centric protocols</h3>\n<p>The number of assessments (measures of results or conclusions) in trials has continued to grow due to new advancements in patient-reported outcomes, imaging, data collection, precision medicine, and digital technologies. The average number of assessments in Phase 2 and 3 studies increased from 17 in the period from 2013 to 2016 to 21 in the period from 2017 to 2020.<span class=\"FootNote_footnote-holder__tjRqy\"><a aria-label=\"footnote\" href=\"javascript:void(0);\" class=\"FootNote_footnote-wrapper__AIRwL undefined FootNote_inactive__VZfCp\" aria-describedby=\"0d67c240-964f-4850-b65a-1a21f3fdcd89\"><sup class=\"FootNote_footnotesup__e73z_\">27</sup><span class=\"FootNote_notch-wrapper__b_5NS\"><span class=\"FootNote_notch__omKtY\"></span></span><span class=\"FootNote_tooltip__QtrbA mdc-u-mt-2\"><span class=\"FootNote_footnote-content__r2OVl\"><span id=\"0d67c240-964f-4850-b65a-1a21f3fdcd89\" aria-hidden=\"true\" data-module-theme=\"light\" class=\"FootNote_footnote-text__VjKgO mck-u-links-inline\">Protocol complexity and patient enrollment intensify challenges in oncology trials, <em>Tufts CFSD Impact report</em> 2021, May/June 2021, Volume 23, Number 3; see also Charlie Passut, Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources, CenterWatch, January 18, 2021.</span></span></span></a></span> This places a higher burden on patients, which negatively affects enrollment rates and engagement during the study. To address this, sponsors can conduct patient-burden protocol assessments to optimize study design and make informed choices. They could also use predictive models, past experience, and patient and investigator panels or surveys (for example, a pharma consortiums participant questionnaire on patient satisfaction, experience, and areas for improvement during a clinical trial) to estimate the impact of additional assessments on the overall recruitment rate.</p>\n<h3>3. Take a data-and-analytics approach to site selection and management</h3>\n<p>Sponsors are increasingly using rich data sets of claims, electronic health records, and data from consortia to supplement their own historical data and build sophisticated, AI-driven models to inform country and site selection. These models, which predict the underlying drivers of enrollment for a given indication or therapeutic area, show much greater predictive power than modeling based on historical data alone. According to McKinsey analysis, these models typically can identify opportunities to accelerate recruitment by 15 to 20 percent by predicting sites that will recruit the fastest and reducing sites that wont recruit. AI-driven models better account for factors such as site congestion (how many trials are currently occurring at a given site) and can expand the universe of available sites beyond where the sponsor has worked in the past. They can also create a flywheel effect by giving sponsors insights into how drivers of enrollment affect timelines (for example, how additional target endpoints will affect enrollment speed). Once a trial is under way, real-time performance tracking can identify when sites go dormant, and analytics algorithms can predict when enrollment will end, given the current trajectory and the potential impact of remedial actions.</p>\n<h3>4. Reimagine the point of delivery for clinical trials</h3>\n<p>Traditionally, treatment and monitoring visits for clinical trials have been conducted primarily at major hospitals or government health system hospitals, with sponsors favoring more experienced clinical trial sites. There is now an increasing emphasis on increasing convenience. This can include hybrid trial design to bring elements of the study closer to patients (for example, with home visits, telemedicine, pharmacy visits, and mobile units) and exploring new sites for clinical trials that may be more accessible to patients (including community or rural hospitals, where most patients are treated). When working with less experienced clinical trial sites, sponsors can expect to invest additional time and resources into site training and support, anticipate more questions during the start-up process, and potentially consider simplifying protocols, start-up processes, and site payments to reduce the burden. Exploring new trial sites (both within the United States and in new geographies) allows sponsors to reach pools of patients who might otherwise not have been able to participate in clinical research.</p>\n<h3>5. Reconsider site experience</h3>\n<p>Sponsors can take steps to improve the site experience and thereby position themselves as a sponsor of choice. McKinseys survey of clinical trial PIs has shown that trial enrollment and patient retention are both positively correlated with a high-quality investigator experience (Exhibit 4).</p>\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 4</span></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex4-v3.svgz?cq=50&amp;cpy=Center\"><img alt=\"A higher-quality investigator experience correlates with improved trial performance.\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/accelerating%20clinical%20trials%20to%20improve%20biopharma%20r%20and%20d%20productivity/svgz-accelerating-clinical-trials-ex4-v3.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div>\n<p>One key step in improving site experience is to simplify interactions with sponsors by designating one or a few points of contact to help ensure sites have an integrated experience and know whom to call when inevitable challenges arise. This point of contact can provide each site with bespoke support, which might include staff augmentation (or even chart review), support for physician referrals from nearby treatment locations, or partnership in trial marketing activities. Beyond the human connection, sponsors can use digital tools to provide sites with easy (and immediate) access to trial information, training material, and data on site performance.</p>\n<p>Further, sponsors can reconsider key site facing processes (such as contracting, budgeting, or site initiation) to make these as frictionless as possible. Process simplification will depend on sponsors underlying processes but may include broader use of master service agreements, eliminating confidential disclosure agreements, simplifying budgeting processes, faster decisions on site selection, and greater use of virtual formats for site training.</p>\n<hr>\n<p>Sponsors across the biopharma industry are collectively trying to accelerate clinical trial timelines by two to three years, reduce costs, and retain the highest-quality clinical trials with an enhanced PI and patient experience. Although pursuing the right science and advancing the best clinical assets are fundamental to R&amp;D productivity, increasing patient enrollment and site engagement will ultimately be critical in achieving this ambition. No single change can address all the challenges, but a series of actions (in partnership with global sites) could materially reduce the collective international burden of clinical trials on the industry and patients.</p></div><div class=\"container-placeholder\"></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-xl\"><section role=\"contentinfo\" data-layer-region=\"article-about-authors\" class=\"mdc-u-grid mdc-u-grid-col-md-12 AboutAuthor_mck-c-about-author__nRJzu\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c mdc-u-align-center\">About the author(s)</h5><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-8 mck-u-links-inline mck-u-links-inline--secondary mdc-u-mt-5\"><div><p><strong><a href=\"/our-people/gaurav-agrawal\">Gaurav Agrawal</a></strong> is a senior partner in McKinseys New York office, where <strong><a href=\"/our-people/harriet-keane\">Harriet Keane</a></strong> is a partner and <strong>Amy Silverstein</strong> is an associate partner; <strong>Jacob Kautzky</strong> is a consultant in the Chicago office; <strong><a href=\"/our-people/brandon-parry\">Brandon Parry</a></strong> is a senior partner in the Washington, DC, office; and <strong><a href=\"/our-people/valentina-sartori\">Valentina Sartori</a></strong> is a partner in the Zurich office.</p>\n<p>The authors wish to thank Jeffrey Algazy, Michael Loebl, Piotr Pilarski, Rosa Poetes, Lieven Van der Veken, and Kevin Webster for their contributions to this article.</p></div></div></div></section><section class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-screen-only\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-5 mdc-u-grid-col-lg-end-9\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c mdc-u-align-center\">Explore a career with us</h5><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c mdc-c-link-container--align-center___ar3mu_990311c\"><a data-component=\"mdc-c-link\" href=\"/careers/search-jobs\" class=\"mdc-c-button___U4iY2_990311c mdc-c-button--secondary___Boipq_990311c mdc-c-button--size-large___jwpUy_990311c\" aria-label=\"Search Openings\" data-layer-event-prefix=\"CTA Link\" data-layer-action=\"click\" data-layer-category=\"careers\" data-layer-subcategory=\"search\" data-layer-text=\"Search Openings\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Search Openings</span></a></div></div></section></div></main></div><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"light\" data-module-background=\"lightest-grey\" data-module-category=\"StandalonePromo\" class=\"RelatedArticle_mck-c-article-related__GGA76 mck-u-screen-only\" data-layer-region=\"related-articles\"><div class=\"mdc-o-container__wrapper is-wrapped mdc-u-spaced-mobile\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-u-align-center\">Related Articles</h5><div class=\"mdc-u-grid mdc-u-grid-col-md-3 RelatedArticle_items-container__s2uD0\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/from-bench-to-bedside-transforming-r-and-d-labs-through-automation\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-from-0 { aspect-ratio: 16/9 }</style><img alt=\"Laboratory testing equipment\" class=\"picture-uniqueKey-from-0\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/from%20bench%20to%20bedside%20transforming%20r%20and%20d%20labs%20through%20automation/from-bench-1455924786-ca-1536x1536.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/from-bench-to-bedside-transforming-r-and-d-labs-through-automation\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>From bench to bedside: Transforming R&amp;D labs through automation</div></a></h6></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/ai-in-biopharma-research-a-time-to-focus-and-scale\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-aiin-0 { aspect-ratio: 16/9 }</style><img alt=\"Futuristic laboratory equipment. Rear view of scientist during DNA research\" class=\"picture-uniqueKey-aiin-0\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/ai%20in%20biopharma%20research%20a%20time%20to%20focus%20and%20scale/ai-in-biopharma-research-1295493022-thumb-1536x1536.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/ai-in-biopharma-research-a-time-to-focus-and-scale\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>AI in biopharma research: A time to focus and scale</div></a></h6></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/the-helix-report-is-biopharma-wired-for-future-success\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-theh-0 { aspect-ratio: 16/9 }</style><img alt=\"DNA double helix in glass on blue background\" class=\"picture-uniqueKey-theh-0\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20helix%20report%20is%20biopharma%20wired%20for%20future%20success/the-helix-report-1133773271-standard-1536x1536.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/the-helix-report-is-biopharma-wired-for-future-success\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>The Helix report: Is biopharma wired for future success?</div></a></h6></div></div></div></div></div></div></div></main><div class=\"mck-u-sr-only\" role=\"log\" aria-live=\"polite\" aria-relevant=\"additions\" aria-atomic=\"true\"></div></div><script id=\"__NEXT_DATA__\" type=\"application/json\">{\"props\":{\"pageProps\":{\"locale\":\"en\",\"dictionary\":{},\"sitecoreContext\":{\"route\":{\"name\":\"Accelerating clinical trials to improve biopharma R and D productivity\",\"displayName\":\"Accelerating clinical trials to improve biopharma R and D productivity\",\"fields\":null,\"databaseName\":\"web\",\"deviceId\":\"fe5d7fdf-89c0-4d99-9aa3-b5fbd009c9f3\",\"itemId\":\"b2fcd064-0b5a-441e-99e4-2d8a7bfc375a\",\"itemLanguage\":\"en\",\"itemVersion\":1,\"layoutId\":\"ae753eb4-a035-40b4-83bf-4b4438df6742\",\"templateId\":\"683910db-02ba-40ba-92e7-726c880160a9\",\"templateName\":\"ArticleJSS\",\"placeholders\":{\"jss-main\":[{\"uid\":\"232bb7e9-289f-492d-a916-2b6185e44a84\",\"componentName\":\"ArticleTemplate\",\"dataSource\":\"\",\"fields\":{\"data\":{\"articleTemplate\":{\"title\":{\"jsonValue\":{\"value\":\"Accelerating clinical trials to improve biopharma R\\u0026amp;D productivity\"}},\"sEOTitle\":{\"value\":\"Speed up biopharma clinical trials to boost R\\u0026amp;D output\"},\"description\":{\"jsonValue\":{\"value\":\"Biopharma sponsors are seeking to accelerate clinical trials and reduce costs through a set of targeted actions aimed at improving patient and site engagement and enrollment productivity.\"}},\"sEODescription\":{\"value\":\"Biopharma clinical trial sponsors want to speed up trials through targeted actions to improve patient and site engagement and enrollment productivity\"},\"displayDate\":{\"jsonValue\":{\"value\":\"2024-01-22T00:00:00Z\"}},\"body\":{\"value\":\"[[Audio 1]]\\n[[DownloadsSidebar]]\\n\\u003cp\\u003e\\u003cstrong\\u003eBiopharmaceutical (biopharma) R\\u0026amp;D\\u003c/strong\\u003e stands at an inflection point, with the limiting factor for innovation no longer science or funding but the speed at which clinical trials can be completed because of a shortage of study participants and clinical site professionals such as principal investigators (PIs), site coordinators, and nurses.\\u003c/p\\u003e\\n[[Sidebar authors]]\\n\\u003cp\\u003eIn this environment, the most successful clinical trial sponsors (that is, biopharma manufacturers that are responsible for trial initiation, management, and financing) will be the biopharma companies that evolve their clinical trial delivery model to create a compelling value proposition for study participants and sites. This article explores the barriers to improving R\\u0026amp;D productivity, including long clinical trial timelines and challenges to clinical trial recruitment, and actions sponsors can take to increase trial participants and improve the experience of clinical trial sites.\\u003c/p\\u003e\\n\\u003ch2\\u003eA golden era for biopharma innovation\\u003c/h2\\u003e\\n[[MostPopularArticles 5]]\\n\\u003cp\\u003eToday, the biopharma industry has its largest and most diverse clinical pipeline in history, the culmination of decades of innovative research. The total number of distinct drugs in development grew from 3,200 in 2012 to 6,100 in 2022.[[footnote 1]] Furthermore, this pipeline is increasingly diverse; 14 percent of assets use modalities validated over the past five years (predominantly various forms of cell and gene therapy).[[footnote 2]]\\u003c/p\\u003e\\n\\u003cp\\u003eThe ability to deliver on this expansive pipeline has been enabled by government investment\\u0026mdash;including an estimated $18 billion made available for Operation Warp Speed and $48 billion invested each year by the National Institutes of Health alone[[footnote 3]]\\u0026mdash;and private markets, with an estimated $146 billion in life sciences venture capital funding in the past three years.[[footnote 4]]\\u003c/p\\u003e\\n\\u003ch2\\u003eLow R\\u0026amp;D productivity driven by lengthy clinical trial timelines and increasing trial costs\\u003c/h2\\u003e\\n\\u003cp\\u003eAlthough the current climate for biopharma innovation is seemingly ideal, with 4,300 clinical trials starting in 2022 alone, R\\u0026amp;D productivity remains stubbornly low. From 2012 to 2022, inflation-adjusted industry R\\u0026amp;D spending increased 44 percent, from about $170 billion to $247 billion, (Exhibit 1).[[footnote 5]] However, the number of US novel drug approvals remains flat at an average of 43 per year, meaning the attrition-adjusted cost to develop a single novel asset is now estimated to be as high as $2.8 billion.[[footnote 6]]\\u003c/p\\u003e\\n[[Exhibit 1]]\\n\\u003cp\\u003eMultiple factors underlie low R\\u0026amp;D productivity, including consistently low success rates; only about 13 percent of assets that enter the Phase 1 trial stage go on to launch.[[footnote 7]] In addition, development costs remain high (accounting for as much as 60 to 70 percent of total costs)[[footnote 8]] and development cycles are long (taking an average of 12 years to develop a novel medicine).[[footnote 9]] Furthermore, development timelines have extended. For example, according to McKinsey analysis, between the periods of 2011 to 2015 and 2016 to 2021, the average clinical trial lengthened from 41 to 44 months for Phase 3 trials and from 37 to 41 months for Phase 2 trials.[[footnote 10]] Today, it is estimated that up to 80 percent of clinical trials fail to finish on time.[[footnote 11]] At the same time, speed of clinical development is critical for biopharma companies and patients. For companies, the rise in \\u0026ldquo;herding,\\u0026rdquo; in which multiple companies focus on the same high-potential mechanisms of action (MoAs), increases the pressure to be first to market. Over the past 20 years, the top five most active MoAs in a given year saw an almost fivefold increase in the number of assets being developed, with the first product to market achieving outsize success.[[footnote 12]] Furthermore, the passage of the US Inflation Reduction Act, which includes provisions to reduce drug prices, will influence which indications companies pursue and increase the importance of being first to market.\\u003c/p\\u003e\\n\\u003cp\\u003eFor patients with many indications, unmet need remains acute; more than 6,000 rare diseases have no known therapy,[[footnote 13]] and numerous cancers (for example, pancreatic cancers, mesotheliomas, and brain cancers) have a five-year survival rate of less than 35 percent.[[footnote 14]] For a pharma company with three to five investigational drugs entering first in human studies each year, a 12-month development acceleration applied across the portfolio can translate to more than $400 million in net present value for the sponsor and deliver incalculable benefits for patients and their families.[[footnote 15]]\\u003c/p\\u003e\\n\\u003ch2\\u003eChallenges in recruitment for clinical trials\\u003c/h2\\u003e\\n\\u003cp\\u003eAlthough there are multiple levers to pull to improve R\\u0026amp;D productivity, development acceleration is one R\\u0026amp;D leaders can explore immediately and one that can have a greater impact on patients. In clinical trials, treatment durations are often fixed, and study start-up and close-out account for only a small portion of overall trial duration (with best-in-class timelines of about two months and one month, respectively).\\u003c/p\\u003e\\n\\u003cp\\u003eTherefore, the biggest opportunity for sponsors to accelerate clinical trials is to increase the speed    and improve the efficiency of clinical trial enrollment; however, participant recruitment is increasingly difficult. For example, the rate of clinical trial participants enrolled per site per month in oncology and nononcology Phase 3 trials declined by 14 percent and 54 percent, respectively, in the periods 2012 to 2014 and 2021 to 2023 (Exhibit 2).\\u003c/p\\u003e\\n[[Exhibit 2]]\\n\\u003cp\\u003eFactors contributing to enrollment challenges exist on both the sponsor and site side of the equation. Sponsors require more participants than ever and are defining eligibility more specifically. Meanwhile, more complex protocols have increased the demands placed on sites at a time when clinical trial site staff turnover (PIs, clinical trial coordinators, and nurses) is at an all-time high,[[footnote 16]] and physicians are less motivated to participate in clinical research because of changes to incentive models.\\u003c/p\\u003e\\n\\u003ch3\\u003eIncreasing demand for trial participants\\u003c/h3\\u003e\\n\\u003cp\\u003eAccording to McKinsey analysis, over the past decade demand for trial participants has increased almost 10 percent as a result of more and larger trials; comparing 2019 to 2022, the total target enrollment of trials starting in those years grew 18 percent, from 2.2 million to 2.6 million (Exhibit 3).\\u003c/p\\u003e\\n[[Exhibit 3]]\\n\\u003cp\\u003eMoreover, demand is spread unevenly, with disproportionately high trial volumes compared to overall incidence for some indications (for instance, multiple myeloma, cystic fibrosis, multiple sclerosis, non-Hodgkin lymphoma, and thalassemia).\\u003c/p\\u003e\\n\\u003cp\\u003eOncology poses a particular challenge; the number of required participants has increased from about 1.1 million in 2019 to about 1.3 million in 2022.[[footnote 17]] (As a point of comparison, an estimated 1.9 million individuals were diagnosed with cancer in the United States in 2022.)[[footnote 18]] Despite this considerable clinical research activity, only about 6 percent of US cancer patients are estimated to participate in a clinical trial. This participation rate is only 4 percent for patients receiving care at non\\u0026ndash;National Cancer Institute (NCI) centers compared to 19 percent at NCI centers.[[footnote 19]] These trends in concentration of care are applicable across the world, including in other geographies where clinical trials are commonly run (for example, Eastern Europe and Western Europe).\\u003c/p\\u003e\\n\\u003cp\\u003eThe enrollment challenge is further exacerbated by an increased focus on precision medicine, whereby study groups are tightly defined with the goal of developing medicines that are highly effective in subsets of participants.[[footnote 20]] For example, as of 2022, more than half of oncology trials are estimated to have a biomarker-defined target subpopulation.[[footnote 21]] This is the case even with indications traditionally viewed as homogenous, such as lung cancer, which has more than ten subpopulations being investigated in clinical trials.[[footnote 22]]\\u003c/p\\u003e\\n\\u003cp\\u003eThese industry-wide dynamics have made recruiting increasingly challenging. Whereas a site may have only a handful of (or zero) eligible participants for a given study, the time and financial burden of standing up a clinical trial at even a single site is undiminished for sponsor and site.\\u003c/p\\u003e\\n\\u003ch3\\u003eRising burden on sites\\u003c/h3\\u003e\\n\\u003cp\\u003eAs sponsors strive to generate more compelling data packages for regulators and internal translational research (to inform the next generation of drug discovery), the burden on sites has continued to rise. As a measure of trial complexity, the average number of Phase 2 and Phase 3 endpoints (specifically desired measurements of clinical trial outcomes) has increased from 17 in the period from 2013 to 2016 to about 21 in the period from 2017 to 2020,[[footnote 23]] with many endpoints requiring specific equipment or training at the site level. Furthermore, although growing adoption of eClinical technologies theoretically reduces dependence on paper forms, sites typically need to implement or integrate five or more systems\\u0026mdash;including electronic data capture, electronic clinical outcome assessments, and electronic consent forms\\u0026mdash;before they can start to recruit study participants.\\u003c/p\\u003e\\n\\u003ch3\\u003eChallenging physician incentives\\u003c/h3\\u003e\\n\\u003cp\\u003eThe United States continues to remain an important geography for clinical trials, with more than 83 percent of global Phase 3 industry-sponsored trials having at least one US site.[[footnote 24]] While all physicians are determined to deliver the best possible care, current incentive models can make participation in clinical trials challenging. For example, in the United States, most physicians are assessed by Centers for Medicare and Medicaid Services (CMS) using a model based on Relative Value Units, which puts a low premium on clinical research activity. Furthermore, at a provider level, income from clinical research patient visits is often marginal in terms of overall revenue versus traditional standard-of-care visits.\\u003c/p\\u003e\\n\\u003cp\\u003eGlobal turnover of healthcare staff (including PIs, trial coordinators, and nurses) is at an all-time high; an estimated 50 percent of clinical trial PIs participated in only one clinical trial between 1999 and 2015, a trend that predates the Great Resignation of the past few years.[[footnote 25]] All of this contributes to the fact that more than two-thirds of global PIs remain \\u0026ldquo;one and done\\u0026rdquo; clinical trial investigators\\u0026mdash;a persistent trend over the past decade.[[footnote 26]]\\u003c/p\\u003e\\n\\u003ch2\\u003eFive opportunities to accelerate recruitment to boost overall R\\u0026amp;D productivity\\u003c/h2\\u003e\\n\\u003cp\\u003eAlthough addressing challenges of physician burnout and misaligned incentive models may be beyond the scope of most sponsors, the biopharma industry can take meaningful action to accelerate clinical trial recruitment. Sponsors can explore five areas in particular to answer this question: What would it take to make trial sizes 20 percent smaller than five years ago, cut recruitment timelines in half, and keep costs the same?\\u003c/p\\u003e\\n\\u003ch3\\u003e1. Apply innovative trial designs to reduce total required study participants\\u003c/h3\\u003e\\n\\u003cp\\u003eMinimizing the number of participants exposed to experimental therapies is a common goal of regulators and sponsors. Increased use of statistical innovation and predictive modeling\\u0026mdash;to optimize the number of clinical trial experimental groups and better estimate trial size to avoid statistical overpowering\\u0026mdash;can effectively help achieve this goal. Likewise, although not yet widespread, use of real-world evidence (such as borrowed algorithms) to supplement participants\\u0026rsquo; data has significant potential to reduce the number of required participants by enriching \\u0026ldquo;control arms\\u0026rdquo; (control patients) while not going as far as full synthetic controls (controls created using real-world data rather than actual enrollees). Additionally, sponsors continue to expand the use cases for innovative trial design beyond oncology. This includes umbrella studies to investigate multiple therapies in a single study (with the possibility to add arms as standard of care evolves), Bayesian clinical trials to reduce the number of clinical trial participants over the length of the study, and basket or multi-indication trials to more efficiently test novel therapies.\\u003c/p\\u003e\\n\\u003ch3\\u003e2. Differentiate with simpler, patient-centric protocols\\u003c/h3\\u003e\\n\\u003cp\\u003eThe number of assessments (measures of results or conclusions) in trials has continued to grow due to new advancements in patient-reported outcomes, imaging, data collection, precision medicine, and digital technologies. The average number of assessments in Phase 2 and 3 studies increased from 17 in the period from 2013 to 2016 to 21 in the period from 2017 to 2020.[[footnote 27]] This places a higher burden on patients, which negatively affects enrollment rates and engagement during the study. To address this, sponsors can conduct patient-burden protocol assessments to optimize study design and make informed choices. They could also use predictive models, past experience, and patient and investigator panels or surveys (for example, a pharma consortium\\u0026rsquo;s participant questionnaire on patient satisfaction, experience, and areas for improvement during a clinical trial) to estimate the impact of additional assessments on the overall recruitment rate.\\u003c/p\\u003e\\n\\u003ch3\\u003e3. Take a data-and-analytics approach to site selection and management\\u003c/h3\\u003e\\n\\u003cp\\u003eSponsors are increasingly using rich data sets of claims, electronic health records, and data from consortia to supplement their own historical data and build sophisticated, AI-driven models to inform country and site selection. These models, which predict the underlying drivers of enrollment for a given indication or therapeutic area, show much greater predictive power than modeling based on historical data alone. According to McKinsey analysis, these models typically can identify opportunities to accelerate recruitment by 15 to 20 percent by predicting sites that will recruit the fastest and reducing sites that won\\u0026rsquo;t recruit. AI-driven models better account for factors such as site congestion (how many trials are currently occurring at a given site) and can expand the universe of available sites beyond where the sponsor has worked in the past. They can also create a flywheel effect by giving sponsors insights into how drivers of enrollment affect timelines (for example, how additional target endpoints will affect enrollment speed). Once a trial is under way, real-time performance tracking can identify when sites go dormant, and analytics algorithms can predict when enrollment will end, given the current trajectory and the potential impact of remedial actions.\\u003c/p\\u003e\\n\\u003ch3\\u003e4. Reimagine the point of delivery for clinical trials\\u003c/h3\\u003e\\n\\u003cp\\u003eTraditionally, treatment and monitoring visits for clinical trials have been conducted primarily at major hospitals or government health system hospitals, with sponsors favoring more experienced clinical trial sites. There is now an increasing emphasis on increasing convenience. This can include hybrid trial design to bring elements of the study closer to patients (for example, with home visits, telemedicine, pharmacy visits, and mobile units) and exploring new sites for clinical trials that may be more accessible to patients (including community or rural hospitals, where most patients are treated). When working with less experienced clinical trial sites, sponsors can expect to invest additional time and resources into site training and support, anticipate more questions during the start-up process, and potentially consider simplifying protocols, start-up processes, and site payments to reduce the burden. Exploring new trial sites (both within the United States and in new geographies) allows sponsors to reach pools of patients who might otherwise not have been able to participate in clinical research.\\u003c/p\\u003e\\n\\u003ch3\\u003e5. Reconsider site experience\\u003c/h3\\u003e\\n\\u003cp\\u003eSponsors can take steps to improve the site experience and thereby position themselves as a \\u0026ldquo;sponsor of choice.\\u0026rdquo; McKinsey\\u0026rsquo;s survey of clinical trial PIs has shown that trial enrollment and patient retention are both positively correlated with a high-quality investigator experience (Exhibit 4).\\u003c/p\\u003e\\n[[Exhibit 4]]\\n\\u003cp\\u003eOne key step in improving site experience is to simplify interactions with sponsors by designating one or a few points of contact to help ensure sites have an integrated experience and know whom to call when inevitable challenges arise. This point of contact can provide each site with bespoke support, which might include staff augmentation (or even chart review), support for physician referrals from nearby treatment locations, or partnership in trial marketing activities. Beyond the human connection, sponsors can use digital tools to provide sites with easy (and immediate) access to trial information, training material, and data on site performance.\\u003c/p\\u003e\\n\\u003cp\\u003eFurther, sponsors can reconsider key site facing processes (such as contracting, budgeting, or site initiation) to make these as frictionless as possible. Process simplification will depend on sponsors\\u0026rsquo; underlying processes but may include broader use of master service agreements, eliminating confidential disclosure agreements, simplifying budgeting processes, faster decisions on site selection, and greater use of virtual formats for site training.\\u003c/p\\u003e\\n\\u003chr /\\u003e\\n\\u003cp\\u003eSponsors across the biopharma industry are collectively trying to accelerate clinical trial timelines by two to three years, reduce costs, and retain the highest-quality clinical trials with an enhanced PI and patient experience. Although pursuing the right science and advancing the best clinical assets are fundamental to R\\u0026amp;D productivity, increasing patient enrollment and site engagement will ultimately be critical in achieving this ambition. No single change can address all the challenges, but a series of actions (in partnership with global sites) could materially reduce the collective international burden of clinical trials on the industry and patients.\\u003c/p\\u003e\"},\"isFullScreenInteractive\":{\"boolValue\":false},\"hideStickySocialShareBar\":{\"boolValue\":false},\"desktopID\":{\"value\":\"\"},\"mobileID\":{\"value\":\"\"},\"desktopURL\":{\"value\":\"\"},\"mobileURL\":{\"value\":\"\"},\"desktopPaddingPercentage\":{\"value\":\"\"},\"mobilePaddingPercentage\":{\"value\":\"\"},\"desktopOverrideHeight\":{\"value\":\"\"},\"mobileOverrideHeight\":{\"value\":\"\"},\"cerosOembedURL\":{\"value\":\"\"},\"cerosRenderMode\":{\"targetItem\":null},\"cerosBackgroundColor\":{\"targetItem\":null},\"hideByLine\":{\"boolValue\":true},\"tableOfContentsTitle\":{\"value\":\"TABLE OF CONTENTS\"},\"accessStatus\":{\"targetItem\":{\"key\":{\"value\":\"RegisteredUsers\"},\"value\":{\"value\":\"Registered Users\"}}},\"articleType\":{\"targetItem\":{\"displayName\":\"Article\"}},\"hasSpecialReport\":{\"boolValue\":false},\"contentType\":{\"targetItem\":{\"displayName\":\"Article\"}},\"sourcePublication\":{\"targetItem\":null},\"externalPublication\":{\"value\":\"\"},\"mobileReady\":{\"boolValue\":true},\"forClientsOnly\":{\"boolValue\":false},\"excludeFromClientLink\":{\"boolValue\":false},\"originalPublishDate\":{\"jsonValue\":{\"value\":\"2024-01-22T00:00:00Z\"}},\"footnotes\":{\"value\":\"\\u003col\\u003e\\n    \\u003cli\\u003eBased on McKinsey analysis of PharmaProjects data 2022.\\u003c/li\\u003e\\n    \\u003cli\\u003eBased on McKinsey analysis of PharmaProjects data 2022.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u0026ldquo;Operation Warp Speed: Implications for global vaccine security,\\u0026rdquo; \\u003cem\\u003eThe Lancet Global Health\\u003c/em\\u003e, March 26, 2021; \\u0026ldquo;Budget,\\u0026rdquo; National Institutes of Health, reviewed October 24, 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003eMcKinsey analysis of BioCentury Inc., accessed February 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003eBased on McKinsey analysis of data from Pharmaprojects, 2022 and Evaluate Pharma, August 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u0026ldquo;CDER\\u0026rsquo;s annual novel drug approvals: 2013 \\u0026ndash; 2022,\\u0026rdquo; New Drug Therapy Approvals 2022, U.S. Food \\u0026amp; Drug Administration, current as of January 10, 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003eMcKinsey analysis.\\u003c/li\\u003e\\n    \\u003cli\\u003e2022 PhRMA Annual Membership Survey, PhRMA.\\u003c/li\\u003e\\n    \\u003cli\\u003eGaurav Agrawal, Felix Bader, Jan G\\u0026uuml;nthner, and Stephan Wurzer, \\u0026ldquo;\\u003ca href=\\\"/industries/life-sciences/our-insights/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\\\"\\u003eFast to first-in-human: Getting new medicines to patients more quickly\\u003c/a\\u003e,\\u0026rdquo; McKinsey, February 10, 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u0026ldquo;Protocol design scope and execution burden continue to rise, most notably in Phase III,\\u0026rdquo; \\u003cem\\u003eTufts CFSD Impact report\\u003c/em\\u003e, May/June 2023, Volume 25, Number 3; Jason Scott, \\u0026ldquo;Phase 3 trials significantly rising in complexity, says CSDD,\\u0026rdquo; CenterWatch, May 15, 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003eMette Br\\u0026oslash;gger-Mikkelsen et al., \\u0026ldquo;Online patient recruitment in clinical trials: Systematic review and meta-analysis,\\u0026rdquo; \\u003cem\\u003eJournal of Medical Internet Research\\u003c/em\\u003e, November 2020.\\u003c/li\\u003e\\n    \\u003cli\\u003eChristian Fougner et al., \\u0026ldquo;Herding in the drug development pipeline,\\u0026rdquo; \\u003cem\\u003eNature Reviews Drug Discovery\\u003c/em\\u003e, April 28, 2023, Volume 22.\\u003c/li\\u003e\\n    \\u003cli\\u003eMcKinsey analysis of Orphanet.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u0026ldquo;Cancer stat facts: Pancreatic cancer,\\u0026rdquo; Surveillance, Epidemiology, and End Results Program (SEER), National Cancer Institute, accessed November 2023; \\u0026ldquo;Survival rates for malignant mesothelioma,\\u0026rdquo; American Cancer Society, last revised March 2, 2023; \\u0026ldquo;Cancer stat facts: Brain and other nervous system cancer,\\u0026rdquo; SEER, National Cancer Institute, accessed November 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003eGaurav Agrawal, Felix Bader, Jan G\\u0026uuml;nthner, and Stephan Wurzer, \\u0026ldquo;\\u003ca href=\\\"/industries/life-sciences/our-insights/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\\\"\\u003eFast to first-in-human: Getting new medicines to patients more quickly\\u003c/a\\u003e,\\u0026rdquo; McKinsey, February 10, 2023.\\u003c/li\\u003e\\n    \\u003cli\\u003eGrace Sun et al., \\u0026ldquo;Crisis of the clinical trials staff attrition after the COVID-19 pandemic,\\u0026rdquo; \\u003cem\\u003eJCO Oncology Practice\\u003c/em\\u003e, August 1, 2023, Volume 19, Number 8.\\u003c/li\\u003e\\n    \\u003cli\\u003eBased on McKinsey analysis including all trials currently recruiting for breast cancer, cervical cancer, CRC, leukemia, melanoma, multiple myeloma, NHL, NSCLC, prostate cancer, and renal cell carcinoma.\\u003c/li\\u003e\\n    \\u003cli\\u003eRebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs, and Ahmedin Jemal, \\u0026ldquo;Cancer statistics, 2022,\\u0026rdquo; \\u003cem\\u003eCA: A Cancer Journal for Clinicians\\u003c/em\\u003e, January 12, 2022.\\u003c/li\\u003e\\n    \\u003cli\\u003eJoseph M. Unger and Mark Fleury, \\u0026ldquo;Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer,\\u0026rdquo; \\u003cem\\u003eJournal of Clinical Oncology\\u003c/em\\u003e, September 2021, Volume 39.\\u003c/li\\u003e\\n    \\u003cli\\u003eChristian Fougner et al., \\u0026ldquo;Herding in the drug development pipeline,\\u0026rdquo; \\u003cem\\u003eNature Reviews Drug Discovery\\u003c/em\\u003e, April 28, 2023, Volume 22.\\u003c/li\\u003e\\n    \\u003cli\\u003eJurgita Gammall and Alvina G. Lai, \\u0026ldquo;Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review,\\u0026rdquo; \\u003cem\\u003enpj Precision Oncology\\u003c/em\\u003e, April 20, 2022.\\u003c/li\\u003e\\n    \\u003cli\\u003eShenduo Li et al., \\u0026ldquo;Emerging targeted therapies in advanced non-small-cell lung cancer,\\u0026rdquo; \\u003cem\\u003eCancers (Basel)\\u003c/em\\u003e, June 2023, Volume 15, Number 11, Epidermal Growth Factor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene encoding a type I (ROS1), proto-oncogene B-Raf (BRAF), Neurotrophic tyrosine receptor kinase (NTRK), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 (HER-2), and Programmed Cell Death Ligand 1 (PD-L1).\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u0026ldquo;Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Trials,\\u0026rdquo; \\u003cem\\u003eTufts CFSD Impact report\\u003c/em\\u003e, May/June 2021, Volume 23, Number 3; see also Charlie Passut, \\u0026ldquo;Trial complexity, endpoints continue to increase, stretching site resources,\\u0026rdquo; CenterWatch, January 18, 2021.\\u003c/li\\u003e\\n    \\u003cli\\u003eClinicaltrials.gov; McKinsey analysis including all global, non-infectious disease Phase 3 trials completed between 2012 and 2023, with global trials defined as occurring in at least three countries.\\u003c/li\\u003e\\n    \\u003cli\\u003eChristopher B. Fordyce et al., \\u0026ldquo;Trends in clinical trial investigator workforce and turnover: An analysis of the U.S. FDA 1572 BMIS database,\\u0026rdquo; Contemporary Clinical Trials Communications, 2019, Volume 15.\\u003c/li\\u003e\\n    \\u003cli\\u003eKen Gatz, \\u0026ldquo;Tracking change in the global investigative site landscape,\\u0026rdquo; \\u003cem\\u003eApplied Clinical Trials\\u003c/em\\u003e, December 2021, Volume 30, Number 12; James Miessler, \\u0026ldquo;Unprecedented decline in one-and-done PI rate leads to reversal of turnover trend,\\u0026rdquo; CenterWatch, January 10, 2022.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u0026ldquo;Protocol complexity and patient enrollment intensify challenges in oncology trials,\\u0026rdquo; \\u003cem\\u003eTufts CFSD Impact report\\u003c/em\\u003e 2021, May/June 2021, Volume 23, Number 3; see also Charlie Passut, \\u0026ldquo;Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources,\\u0026rdquo; CenterWatch, January 18, 2021.\\u003c/li\\u003e\\n\\u003c/ol\\u003e\"},\"contributoryPractice\":{\"targetItems\":[{\"displayName\":\"Life Sciences\"}]},\"aboutTheAuthors\":{\"value\":\"\\u003cp\\u003e\\u003cstrong\\u003e\\u003ca href=\\\"/our-people/gaurav-agrawal\\\"\\u003eGaurav Agrawal\\u003c/a\\u003e\\u003c/strong\\u003e is a senior partner in McKinsey\\u0026rsquo;s New York office, where \\u003cstrong\\u003e\\u003ca href=\\\"/our-people/harriet-keane\\\"\\u003eHarriet Keane\\u003c/a\\u003e\\u003c/strong\\u003e is a partner and \\u003cstrong\\u003eAmy Silverstein\\u003c/strong\\u003e is an associate partner; \\u003cstrong\\u003eJacob Kautzky\\u003c/strong\\u003e is a consultant in the Chicago office; \\u003cstrong\\u003e\\u003ca href=\\\"/our-people/brandon-parry\\\"\\u003eBrandon Parry\\u003c/a\\u003e\\u003c/strong\\u003e is a senior partner in the Washington, DC, office; and \\u003cstrong\\u003e\\u003ca href=\\\"/our-people/valentina-sartori\\\"\\u003eValentina Sartori\\u003c/a\\u003e\\u003c/strong\\u003e is a partner in the Zurich office.\\u003c/p\\u003e\\n\\u003cp\\u003eThe authors wish to thank Jeffrey Algazy, Michael Loebl, Piotr Pilarski, Rosa Poetes, Lieven Van der Veken, and Kevin Webster for their contributions to this article.\\u003c/p\\u003e\"},\"authors\":{\"targetItems\":[{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"E3EC80033372419CAF4A9B4D7676A7F0\",\"name\":\"Gaurav Agrawal\",\"authorTitle\":{\"value\":\"Gaurav Agrawal\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[{\"standardImage\":{\"src\":\"/~/media/mckinsey/our people/guarav agrawal/gaurav-agrawal_fc-mask_profile_1536x1152.jpg\",\"alt\":\"Guarav Agrawal\"},\"emailLinks\":{\"value\":\"Gaurav_Agrawal@mckinsey.com\"},\"linkedInUrl\":{\"value\":\"https://www.linkedin.com/in/gaurav-agrawal-980033a/\"},\"description\":{\"value\":\"Serves biotechnology and pharmaceutical companies, global health institutions, and public sector clients in developing cutting-edge innovation strategies, improving R\\u0026D productivity, and pursuing growth strategies; coleads our work in product development excellence globally\"},\"locations\":{\"targetItems\":[{\"name\":\"New York\",\"displayName\":\"New York\"}]},\"firmTitle\":{\"value\":\"Partner\"},\"thumbnailImage\":{\"alt\":\"Guarav Agrawal\",\"src\":\"/~/media/mckinsey/our people/guarav agrawal/gaurav-agrawal_fc-mask_headshot_988x741.jpg\"},\"url\":{\"path\":\"/our-people/gaurav-agrawal\"}}]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"2C977A0E457548FCB315F7839D280A89\",\"name\":\"Harriet Keane\",\"authorTitle\":{\"value\":\"Harriet Keane\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[{\"standardImage\":{\"src\":\"/~/media/mckinsey/our people/harriet keane/harriet-keane_profile_1536x1152.jpg\",\"alt\":\"Harriet Keane\"},\"emailLinks\":{\"value\":\"Harriet_Keane@mckinsey.com\"},\"linkedInUrl\":{\"value\":\"https://www.linkedin.com/in/harriet-keane-127ab345/\"},\"description\":{\"value\":\"Helps pharmaceutical and biotechnology companies deliver novel therapies to patients via portfolio strategy, development acceleration, operating model, and R\\u0026D; experience across therapeutic areas with expertise in oncology\"},\"locations\":{\"targetItems\":[{\"name\":\"New York\",\"displayName\":\"New York\"}]},\"firmTitle\":{\"value\":\"Partner\"},\"thumbnailImage\":{\"alt\":\"Harriet Keane\",\"src\":\"/~/media/mckinsey/our people/harriet keane/harriet-keane_headshot_988x741.jpg\"},\"url\":{\"path\":\"/our-people/harriet-keane\"}}]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"0794C3F25E10473980C46052790539BB\",\"name\":\"Brandon Parry\",\"authorTitle\":{\"value\":\"Brandon Parry\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[{\"standardImage\":{\"src\":\"/~/media/mckinsey/our people/brandon parry/brandon parry_profile_1536x1152.jpg\",\"alt\":\"Brandon Parry\"},\"emailLinks\":{\"value\":\"Brandon_Parry@mckinsey.com\"},\"linkedInUrl\":{\"value\":\"\"},\"description\":{\"value\":\"Expert in biopharma research and development, serving a wide range of public- and private-sector clients on pivotal strategic, operational, and organizational topics globally\"},\"locations\":{\"targetItems\":[{\"name\":\"Washington DC\",\"displayName\":\"Washington DC\"}]},\"firmTitle\":{\"value\":\"Senior Partner\"},\"thumbnailImage\":{\"alt\":\"Brandon Parry\",\"src\":\"/~/media/mckinsey/our people/brandon parry/brandon parry_headshot_988x741.jpg\"},\"url\":{\"path\":\"/our-people/brandon-parry\"}}]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"7FB82F7C59F74D6FB9FA862D391B6B43\",\"name\":\"Valentina Sartori\",\"authorTitle\":{\"value\":\"Valentina Sartori\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[{\"standardImage\":{\"src\":\"/~/media/mckinsey/our people/valentina sartori/valentina_sartori_standard_profile_1536x1152.jpg\",\"alt\":\"Valentina Sartori\"},\"emailLinks\":{\"value\":\"Valentina_Sartori@mckinsey.com\"},\"linkedInUrl\":{\"value\":\"https://www.linkedin.com/in/valentina-sartori-216b99\"},\"description\":{\"value\":\"Offers distinctive expertise in pharma R\\u0026D, helping clients to transform their organization, harness external innovation, and boost productivity\"},\"locations\":{\"targetItems\":[{\"name\":\"Zurich\",\"displayName\":\"Zurich\"}]},\"firmTitle\":{\"value\":\"Partner\"},\"thumbnailImage\":{\"alt\":\"Valentina Sartori\",\"src\":\"/~/media/mckinsey/our people/valentina sartori/valentina_sartori_headshot_988x741.jpg\"},\"url\":{\"path\":\"/our-people/valentina-sartori\"}}]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"3C93BF00FF2D42AA83AF62B4CA4BEAE7\",\"name\":\"Jacob Kautzky\",\"authorTitle\":{\"value\":\"Jacob Kautzky\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"5C1FAFC4FB0C4E1BA30C245D24A438F8\",\"name\":\"Amy Silverstein\",\"authorTitle\":{\"value\":\"Amy Silverstein\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}}]},\"nonPartnerAuthors\":{\"targetItems\":[]},\"interactiveToUse\":{\"targetItem\":null},\"enableArticleComponents\":{\"boolValue\":false},\"relatedArticles\":{\"targetItems\":[{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"From bench to bedside: Transforming R\\u0026amp;D labs through automation\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/from-bench-to-bedside-transforming-r-and-d-labs-through-automation\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"Laboratory technology has been a steady runner in the world of pharmaceuticals, rather than a racing star\\u0026mdash;until now. A series of innovations points toward exponential gains in R\\u0026amp;D productivity.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/from bench to bedside transforming r and d labs through automation/from-bench-1455924786-ca-1536x1536.jpg\",\"alt\":\"Laboratory testing equipment\"},\"heroImage\":null,\"thumbnailImage\":null},{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"AI in biopharma research: A time to focus and scale\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/ai-in-biopharma-research-a-time-to-focus-and-scale\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"By focusing on specific scientific and operational pain points and fully integrating AI into research workflows, biopharma companies can deliver greater patient impact and significant value.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/ai in biopharma research a time to focus and scale/ai-in-biopharma-research-1295493022-thumb-1536x1536.jpg\",\"alt\":\"Futuristic laboratory equipment. Rear view of scientist during DNA research\"},\"heroImage\":null,\"thumbnailImage\":null},{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"The Helix report: Is biopharma wired for future success?\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/the-helix-report-is-biopharma-wired-for-future-success\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"The biopharmaceutical industry has made remarkable achievements in the past decade, but is it equipped to leap still further ahead in the coming one? Company leaders\\u0026rsquo; answers to nine questions could prove decisive.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the helix report is biopharma wired for future success/the-helix-report-1133773271-standard-1536x1536.jpg\",\"alt\":\"DNA double helix in glass on blue background\"},\"heroImage\":null,\"thumbnailImage\":null}]},\"useEnhancedAuthors\":{\"boolValue\":false},\"acknowledgements\":{\"value\":\"\"},\"showSocialShareFooter\":{\"boolValue\":false},\"template\":{\"id\":\"683910db-02ba-40ba-92e7-726c880160a9\"},\"hideFromSearchEngines\":{\"boolValue\":false},\"heroFiftyFiftyBackground\":{\"targetItem\":null},\"backgroundColor\":{\"targetItem\":null},\"gradientDirection\":{\"targetItem\":{\"key\":{\"value\":\"Bottom Right\"},\"value\":{\"value\":\"bottom-right\"}}},\"hideStickySubscriptionBar\":{\"value\":false},\"enableRegWall\":{\"boolValue\":false},\"timer\":{\"value\":\"8\"},\"regWallHeading\":{\"value\":\"\"},\"showGoToHomeLink\":{\"boolValue\":true},\"regWallDescription\":{\"value\":\"\"},\"isInsightsStorePage\":{\"boolValue\":false},\"selectedModalSubscriptions\":{\"targetItems\":[]},\"link1\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link2\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link3\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link4\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link5\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"fullReportPDF\":{\"name\":\"Full Report PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"fullReportPDFDisplayName\":{\"value\":\"\"},\"appendixPDF\":{\"name\":\"Appendix PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"appendixPDFDisplayName\":{\"value\":\"\"},\"articlePDF\":{\"name\":\"Article PDF\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity.pdf\",\"displayName\":\"accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\",\"title\":\"Accelerating clinical trials to improve biopharma R\\u0026D productivity\",\"keywords\":\"\",\"description\":\"\",\"extension\":\"pdf\",\"mimeType\":\"application/pdf\",\"size\":715785,\"pageCount\":\"10\",\"thumbnailImageSrc\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity_thumbnail.jpeg\"},\"briefingNotePDF\":{\"name\":\"Briefing Note PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"discussionPapersPDF\":{\"name\":\"Discussion Papers PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"executiveSummaryPDF\":{\"name\":\"Executive Summary PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"executiveSummaryPDFDisplayName\":{\"value\":\"\"},\"researchPreviewPDF\":{\"name\":\"Research Preview PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"heroImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/accelerating-clinical-trials-hero-1536x864.jpg\",\"alt\":\"A senior woman sits across the desk from a nurse practitioner as they discuss her medications. She is dressed casually and looking at the nurse as she listens attentively. The nurse is dressed in blue scrubs and has a headscarf on as she holds out the medication and informs the woman about how to take the new medication.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/accelerating-clinical-trials-thumb-1536x1536.jpg\",\"alt\":\"A senior woman sits across the desk from a nurse practitioner as they discuss her medications. She is dressed casually and looking at the nurse as she listens attentively. The nurse is dressed in blue scrubs and has a headscarf on as she holds out the medication and informs the woman about how to take the new medication.\"},\"heroImageTopOffset\":{\"value\":\"\"},\"headerOverlayOpacity\":{\"targetItem\":null},\"heroType\":{\"targetItem\":{\"displayName\":\"Fifty Fifty\"}},\"photoOverlayOpacity\":{\"targetItem\":null},\"hideHero\":{\"boolValue\":false},\"articleHeroVideoId\":{\"value\":\"\"},\"podcastHeroOmnyAudioID\":{\"value\":\"\"},\"heroBespokeInteractiveID\":{\"value\":\"\"},\"bespokeHeroRenderMode\":{\"targetItem\":null},\"audio\":{\"results\":[{\"id\":\"572CC8759230480DB6EBBD4A8C7C8B61\",\"omnyPlayerAudioURL\":{\"value\":\"\"},\"iTunesURL\":{\"value\":\"\"},\"soundcloudAudioFile\":{\"value\":\"1726479255\"},\"displayNumber\":{\"value\":\"\"},\"headline\":{\"jsonValue\":{\"value\":\"\"}},\"mediaEyebrow\":{\"jsonValue\":{\"value\":\"\"}},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"libraryAudioFile\":{\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Center\"},\"value\":{\"value\":\"small-span-center\"}}},\"hideMediaEyebrow\":{\"boolValue\":true},\"mediaID\":{\"value\":\"1\"},\"template\":{\"name\":\"Audio\"}}]},\"disruptor1up\":{\"results\":[{\"mediaID\":{\"value\":\"cop28\"},\"title\":{\"value\":\"Explore COP28 with McKinsey\"},\"description\":{\"value\":\"Join us for a series of dynamic virtual events during COP28. Discover new research, practical strategies, and collaborations across sectors that propel climate action and growth towards net-zero.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/cop/cop28/cop28-page-thumb_1536x1536.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/sustainability/how-we-help-clients/cop/overview\"}]}}},{\"mediaID\":{\"value\":\"attheedge\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eAt the Edge\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/at-the-edge/id1612870236\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3SnUcezwM20nKnzqvUl6iF\"}]}}},{\"mediaID\":{\"value\":\"authortalks\"},\"title\":{\"value\":\"Visit \\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-books/author-talks\\\"\\u003eAuthor Talks\\u003c/a\\u003e\\u003c/em\\u003e to see the full series.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/author talks/authortalks_1536x1536_v1.png\",\"alt\":\"Author Talks\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/author-talks\"}]}}},{\"mediaID\":{\"value\":\"COVID\"},\"title\":{\"value\":\"Explore McKinseys ongoing coverage of the pandemic\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/risk/our insights/covid 19 implications for business/implications-briefing-note-4-standard-1536x1536.jpg\",\"alt\":\"COVID-19: Implications for business\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more about the business impact of coronavirus and how organizations can respond\",\"Title\":\"\",\"Url\":\"/featured-insights/coronavirus-leading-through-the-crisis\"}]}}},{\"mediaID\":{\"value\":\"CE\"},\"title\":{\"value\":\"Customer experience\"},\"description\":{\"value\":\"More insight into creating competitive advantage by putting customers first and managing their journeys.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/public and social sector/our insights/customer experience/customer-experience_22934010_1536x864.jpg\",\"alt\":\"Customer experience\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"driversofdisruption\"},\"title\":{\"value\":\"Want to subscribe to \\u003ca href=\\\"/features/mckinsey-center-for-future-mobility/our-insights/drivers-of-disruption\\\"\\u003e\\u003cem\\u003eDrivers of Disruption\\u003c/em\\u003e\\u003c/a\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/drivers-of-disruption/id1687257324\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5fWXzWmVKacc5I7u9CQsah?si=KQ-wUOSyQlqcnfexExiH9Q\\u0026nd=1\"}]}}},{\"mediaID\":{\"value\":\"JOL\"},\"title\":{\"value\":\"The Journey of Leadership\"},\"description\":{\"value\":\"\\u003cstrong\\u003eHow CEOs Learn to Lead from the Inside Out\\u003c/strong\\u003e\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/dana-maor\\\"\\u003eDana Maor\\u003c/a\\u003e, \\u003ca href=\\\"https://www.linkedin.com/in/hanswernerkaas\\\"\\u003eHans-Werner Kaas\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/kurt-strovink\\\"\\u003eKurt Strovink\\u003c/a\\u003e, and \\u003ca href=\\\"/our-people/ramesh-srinivasan\\\"\\u003eRamesh Srinivasan\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/journey of leadership/journey-of-leadership-book-cover-1536x1536.jpg\",\"alt\":\"The Journey of Leadership book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/journey-of-leadership\"}]}}},{\"mediaID\":{\"value\":\"surveys\"},\"title\":{\"value\":\"McKinsey\\u0026rsquo;s original survey research\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey global surveys/mck-global-survey-landing-1284442931-thumb-1536x1536.jpg\",\"alt\":\"McKinsey Global Surveys\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-global-surveys\"}]}}},{\"mediaID\":{\"value\":\"healthcarepodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eMcKinsey on Healthcare\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-healthcare/id1469979748\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3y1AgAilV4E5Jz0x4wD9O2?si=mLCTUQ2ORTS_LC5gW_htlA\\u0026dl_branch=1\"}]}}},{\"mediaID\":{\"value\":\"myleadershipjourney\"},\"title\":{\"value\":\"My Leadership Journey\"},\"description\":{\"value\":\"A series of conversations with leaders about the people and experiences that shaped them\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/my leadership journey/my leadership journey collection page_131575496_thumb_1536x1536.jpg\",\"alt\":\"My Leadership Journey\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/my-leadership-journey\"}]}}},{\"mediaID\":{\"value\":\"lessonsfromleaders\"},\"title\":{\"value\":\"State of Organizations: Lessons from leaders\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/state of org lessons from leaders/soo-chapter-2-872507320-standard-1536x1536.jpg\",\"alt\":\"\\\"\\\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore more interviews\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/lessons-from-leaders\"}]}}},{\"mediaID\":{\"value\":\"stateoforg\"},\"title\":{\"value\":\"The State of Organizations 2023\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Report overview\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/the-state-of-organizations-2023\"}]}}},{\"mediaID\":{\"value\":\"titaniumeconomy\"},\"title\":{\"value\":\"The Titanium Economy\"},\"description\":{\"value\":\"How Industrial Technology Can Create a Better, Faster, Stronger America\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/asutosh-padhi\\\"\\u003eAsutosh Padhi\\u003c/a\\u003e, Gaurav Batra, and \\u003ca href=\\\"https://fernweh.com/nick-santhanam/\\\"\\u003eNick Santhanam\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/the titanium economy/titanium_3d-1536x1536-hero-trans.png\",\"alt\":\"The Titanium Economy Book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/the-titanium-economy\"}]}}},{\"mediaID\":{\"value\":\"GII\"},\"title\":{\"value\":\"Global Infrastructure Initiative\"},\"description\":{\"value\":\"Convening global leaders in infrastructure and capital projects in pursuit of new solutions\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the global infrastructure initiative/jpg-cpi-improving-construction-productivity-1536x864.jpg\",\"alt\":\"Improving construction productivity\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"http://www.globalinfrastructureinitiative.com/\"}]}}},{\"mediaID\":{\"value\":\"FOApodcast\"},\"title\":{\"value\":\"Subscribe to \\u003ca href=\\\"/featured-insights/future-of-asia/future-of-asia-podcasts\\\"\\u003e\\u003cem\\u003eFuture of Asia Podcasts\\u003c/em\\u003e\\u003c/a\\u003e\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-asia/id1480316959\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/2CZX4AR2DT4hQCFKJG0cCv?si=B20tkrOmQYymuCUhKCQOwA\"}]}}},{\"mediaID\":{\"value\":\"logisticsdisruptors\"},\"title\":{\"value\":\"Logistics Disruptors\"},\"description\":{\"value\":\"Meet the companies shaping how goods will move tomorrow.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/travel logistics and infrastructure/our insights/logistics disruptors/tli-logistics-disruptors-1536x1536.jpeg\",\"alt\":\"illustration autonomous truck driving off into the future\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/travel-logistics-and-infrastructure/our-insights/logistics-disruptors\"}]}}},{\"mediaID\":{\"value\":\"mckinseyexplainers\"},\"title\":{\"value\":\"Looking for direct answers to other complex questions?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey explainers/mckinseyexplainers-flat-thumb-1536x1536.jpg\",\"alt\":\"Circular, white maze filled with white semicircles.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore the full McKinsey Explainers series\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-explainers\"}]}}},{\"mediaID\":{\"value\":\"livesandlegacies\"},\"title\":{\"value\":\"\\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-lives-and-legacies\\\"\\u003eMcKinsey on Lives \\u0026amp; Legacies\\u003c/a\\u003e\\u003c/em\\u003e\"},\"description\":{\"value\":\"Highlighting the lasting impact of leaders and executives\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey on lives and legacies/lives-and-legacies-landing-page-thumb-1536x1536.jpg\",\"alt\":\"McKinsey on Lives \\u0026 Legacies\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore previous obituaries\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-lives-and-legacies\"}]}}},{\"mediaID\":{\"value\":\"Strategy\"},\"title\":{\"value\":\"Strategy in a digital age\"},\"description\":{\"value\":\"Our series on developing corporate and business-unit strategies in a digitally disrupted world.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/our insights/strategy in a digital age/digital-strategy_1536x864_flexpromoimage.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/featured-insights/strategy-in-a-digital-age\"}]}}},{\"mediaID\":{\"value\":\"great\"},\"title\":{\"value\":\"The great re-make: Manufacturing for modern times\"},\"description\":{\"value\":\"This 21-article compendium gives practical insights for manufacturing leaders looking to keep a step ahead of today\\u0026rsquo;s disruptions.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the great remake manufacturing for modern times/jpg-ops-dm-compendium-cover-1536x864.jpg\",\"alt\":\"The great re-make: Manufacturing for modern times\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/capabilities/operations/our-insights/the-great-re-make-manufacturing-for-modern-times-compendium\"}]}}},{\"mediaID\":{\"value\":\"futureofamerica\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eFuture of America\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-america/id1616517376\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/0FpeyjojJTKf2hVtQ3otah\"}]}}},{\"mediaID\":{\"value\":\"governmentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Government\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-government/id1573645359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/61XsO4B2ersroMft8t3KSq\"}]}}},{\"mediaID\":{\"value\":\"podcast\"},\"title\":{\"value\":\"Want to subscribe to the McKinsey Podcast?\\n\"},\"description\":{\"value\":\"\\u003cdiv class=\\\"cta-container -align-horizontal\\\"\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eGoogle Play\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eiTunes\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eStitcher\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn mck-rss-icon\\\"\\u003eRSS\\u003c/a\\u003e\\n\\u003c/div\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[]}}},{\"mediaID\":{\"value\":\"operationspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Operations\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-operations/id1598128813\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/7LYQS2fxAoBmC3LgFNJbi8\"}]}}},{\"mediaID\":{\"value\":\"energyinsights\"},\"title\":{\"value\":\"Speak to an expert about our upstream capabilities\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/oil and gas/how we help clients/energy insights/newsletter-signup-promo-bar-1536x768.jpg\",\"alt\":\"EI newsletter sign up\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"buildingproductspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Building Products\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-building-product/id1735607317\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/79pncGJtBtzz7pFoR6OiH8\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/how-we-help-clients/mckinsey-academy/product-academy/mckinsey-on-building-product\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Talent\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-talent/id1491112396\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5sW4eHEFMbOvAFJjMfN9a6\"}]}}},{\"mediaID\":{\"value\":\"outlook\"},\"title\":{\"value\":\"A longer, more comprehensive version of our Global Oil Supply \\u0026 Demand Outlook is available for purchase upon request.\\n\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast2\"},\"title\":{\"value\":\"McKinsey Talks Talent Podcast\"},\"description\":{\"value\":\"Bryan Hancock, Brooke Weddle, and other talent experts help you navigate a fast-changing landscape and prepare for the future of work by making talent a competitive advantage.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/mckinsey talks talent/mck-mtt-disruptor-full-1536x864-smoke-may-2021.jpg\",\"alt\":\"McKinsey Talks Talent\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"See more episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/mckinsey-talks-talent-podcast\"}]}}},{\"mediaID\":{\"value\":\"investing\"},\"title\":{\"value\":\"Subscribe to McKinsey on Investing\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/private-capital/our-insights/mckinsey-on-investing-issue-1/contact\"}]}}},{\"mediaID\":{\"value\":\"women matter\"},\"title\":{\"value\":\"Subscribe to McKinsey \\u003cem\\u003eWomen Matter Canada\\u003c/em\\u003e\"},\"description\":{\"value\":\"Please subscribe if your organization is interested in learning about participating in future research.\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"customs\"},\"title\":{\"value\":\"This article was written as part of a larger research effort to identify opportunities for improvement and innovation at customs agencies globally.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/public-sector/our-insights/contact\"}]}}},{\"mediaID\":{\"value\":\"tech\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eCreating value beyond the hype\\u003c/span\\u003e\"},\"description\":{\"value\":\"Let\\u0026rsquo;s deliver on the promise of technology from strategy to scale.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/how we help clients/2024/never-just-tech_thumb_1536x1536.jpg\",\"alt\":\"Never just tech\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/mckinsey-digital/how-we-help-clients?cid=njt-ste-crk-mbm-mbm--2403-promo01-njt-bam-web\"}]}}},{\"mediaID\":{\"value\":\"sust\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eMove from plans to progress.\\u003c/span\\u003e\"},\"description\":{\"value\":\"Sustainability matters. Together well make it real.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/sustainability-campaign_promo-thumb_1536x1536.jpg\",\"alt\":\"Move from plans to progress.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/sustainability/how-we-help-clients/?cid=susti24-ste-crk-mbm-m01-other-glb-web\"}]}}},{\"mediaID\":{\"value\":\"nwowpodcast\"},\"title\":{\"value\":\"Subscribe to the New World of Work podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-new-world-of-work/id1319502839?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI\"}]}}},{\"mediaID\":{\"value\":\"globalpodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eThe McKinsey Podcast\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-mckinsey-podcast/id285260960?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4dyjRTP9xzEUPgleo6XjXI\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"YouTube\",\"Title\":\"\",\"Url\":\"https://www.youtube.com/@McKinsey/podcasts\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-podcast\"}]}}},{\"mediaID\":{\"value\":\"Qaudio\"},\"title\":{\"value\":\"Discover and subscribe to McKinsey Quarterly Audio\"},\"description\":{\"value\":\"\\u003cstrong\\u003eFive ways to subscribe:\\u003c/strong\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/mckinsey-quarterly-audio/id1437925222?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5mb2zYJnrPcRrML8gx5doD\"}]}}},{\"mediaID\":{\"value\":\"shortlist\"},\"title\":{\"value\":\"Subscribe to the Shortlist\"},\"description\":{\"value\":\"McKinsey\\u0026rsquo;s new weekly newsletter, featuring must-read content on a range of topics, every Friday\"},\"image\":{\"src\":\"/~/media/mckinsey/email/shortlist/template/shortlist_promo-interrupter-849120982_1536x1536.jpg\",\"alt\":\"the Shortlist\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Get the Shortlist in your inbox\",\"Title\":\"\",\"Url\":\"/user-registration/manage-account/edit-subscriptions\"}]}}},{\"mediaID\":{\"value\":\"retailpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Consumer and Retail\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-consumer-and-retail/id1526250428\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/41D4bro8PPDOGhEgOEJyHB?si=7l3SeYCZQD-7v3toqd9fHQ\"}]}}},{\"mediaID\":{\"value\":\"insurancepodcast\"},\"title\":{\"value\":\"Want to subscribe to the \\u003cem\\u003eMcKinsey on Insurance\\u003c/em\\u003e podcast?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-insurance/id1533196359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5gZ6YKF7n7C9zWaER4mFZ5\"}]}}},{\"mediaID\":{\"value\":\"strategypodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eInside the Strategy Room\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/inside-the-strategy-room/id1422814215?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4TcFfiQ0e6OYuc5kRDLxqj\"}]}}},{\"mediaID\":{\"value\":\"mgipodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eForward Thinking\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/forward-thinking/id1319502839\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI?si=0zvPmiCsQ7SBAPanfpY4aA\\u0026nd=1\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/mgi/forward-thinking\"}]}}}]},\"globalDisruptors\":{\"disruptor1up\":{\"results\":[{\"mediaID\":{\"value\":\"cop28\"},\"title\":{\"value\":\"Explore COP28 with McKinsey\"},\"description\":{\"value\":\"Join us for a series of dynamic virtual events during COP28. Discover new research, practical strategies, and collaborations across sectors that propel climate action and growth towards net-zero.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/cop/cop28/cop28-page-thumb_1536x1536.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/sustainability/how-we-help-clients/cop/overview\"}]}}},{\"mediaID\":{\"value\":\"attheedge\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eAt the Edge\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/at-the-edge/id1612870236\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3SnUcezwM20nKnzqvUl6iF\"}]}}},{\"mediaID\":{\"value\":\"authortalks\"},\"title\":{\"value\":\"Visit \\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-books/author-talks\\\"\\u003eAuthor Talks\\u003c/a\\u003e\\u003c/em\\u003e to see the full series.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/author talks/authortalks_1536x1536_v1.png\",\"alt\":\"Author Talks\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/author-talks\"}]}}},{\"mediaID\":{\"value\":\"COVID\"},\"title\":{\"value\":\"Explore McKinseys ongoing coverage of the pandemic\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/risk/our insights/covid 19 implications for business/implications-briefing-note-4-standard-1536x1536.jpg\",\"alt\":\"COVID-19: Implications for business\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more about the business impact of coronavirus and how organizations can respond\",\"Title\":\"\",\"Url\":\"/featured-insights/coronavirus-leading-through-the-crisis\"}]}}},{\"mediaID\":{\"value\":\"CE\"},\"title\":{\"value\":\"Customer experience\"},\"description\":{\"value\":\"More insight into creating competitive advantage by putting customers first and managing their journeys.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/public and social sector/our insights/customer experience/customer-experience_22934010_1536x864.jpg\",\"alt\":\"Customer experience\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"driversofdisruption\"},\"title\":{\"value\":\"Want to subscribe to \\u003ca href=\\\"/features/mckinsey-center-for-future-mobility/our-insights/drivers-of-disruption\\\"\\u003e\\u003cem\\u003eDrivers of Disruption\\u003c/em\\u003e\\u003c/a\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/drivers-of-disruption/id1687257324\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5fWXzWmVKacc5I7u9CQsah?si=KQ-wUOSyQlqcnfexExiH9Q\\u0026nd=1\"}]}}},{\"mediaID\":{\"value\":\"JOL\"},\"title\":{\"value\":\"The Journey of Leadership\"},\"description\":{\"value\":\"\\u003cstrong\\u003eHow CEOs Learn to Lead from the Inside Out\\u003c/strong\\u003e\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/dana-maor\\\"\\u003eDana Maor\\u003c/a\\u003e, \\u003ca href=\\\"https://www.linkedin.com/in/hanswernerkaas\\\"\\u003eHans-Werner Kaas\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/kurt-strovink\\\"\\u003eKurt Strovink\\u003c/a\\u003e, and \\u003ca href=\\\"/our-people/ramesh-srinivasan\\\"\\u003eRamesh Srinivasan\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/journey of leadership/journey-of-leadership-book-cover-1536x1536.jpg\",\"alt\":\"The Journey of Leadership book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/journey-of-leadership\"}]}}},{\"mediaID\":{\"value\":\"surveys\"},\"title\":{\"value\":\"McKinsey\\u0026rsquo;s original survey research\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey global surveys/mck-global-survey-landing-1284442931-thumb-1536x1536.jpg\",\"alt\":\"McKinsey Global Surveys\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-global-surveys\"}]}}},{\"mediaID\":{\"value\":\"healthcarepodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eMcKinsey on Healthcare\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-healthcare/id1469979748\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3y1AgAilV4E5Jz0x4wD9O2?si=mLCTUQ2ORTS_LC5gW_htlA\\u0026dl_branch=1\"}]}}},{\"mediaID\":{\"value\":\"myleadershipjourney\"},\"title\":{\"value\":\"My Leadership Journey\"},\"description\":{\"value\":\"A series of conversations with leaders about the people and experiences that shaped them\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/my leadership journey/my leadership journey collection page_131575496_thumb_1536x1536.jpg\",\"alt\":\"My Leadership Journey\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/my-leadership-journey\"}]}}},{\"mediaID\":{\"value\":\"lessonsfromleaders\"},\"title\":{\"value\":\"State of Organizations: Lessons from leaders\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/state of org lessons from leaders/soo-chapter-2-872507320-standard-1536x1536.jpg\",\"alt\":\"\\\"\\\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore more interviews\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/lessons-from-leaders\"}]}}},{\"mediaID\":{\"value\":\"stateoforg\"},\"title\":{\"value\":\"The State of Organizations 2023\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Report overview\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/the-state-of-organizations-2023\"}]}}},{\"mediaID\":{\"value\":\"titaniumeconomy\"},\"title\":{\"value\":\"The Titanium Economy\"},\"description\":{\"value\":\"How Industrial Technology Can Create a Better, Faster, Stronger America\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/asutosh-padhi\\\"\\u003eAsutosh Padhi\\u003c/a\\u003e, Gaurav Batra, and \\u003ca href=\\\"https://fernweh.com/nick-santhanam/\\\"\\u003eNick Santhanam\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/the titanium economy/titanium_3d-1536x1536-hero-trans.png\",\"alt\":\"The Titanium Economy Book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/the-titanium-economy\"}]}}},{\"mediaID\":{\"value\":\"GII\"},\"title\":{\"value\":\"Global Infrastructure Initiative\"},\"description\":{\"value\":\"Convening global leaders in infrastructure and capital projects in pursuit of new solutions\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the global infrastructure initiative/jpg-cpi-improving-construction-productivity-1536x864.jpg\",\"alt\":\"Improving construction productivity\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"http://www.globalinfrastructureinitiative.com/\"}]}}},{\"mediaID\":{\"value\":\"FOApodcast\"},\"title\":{\"value\":\"Subscribe to \\u003ca href=\\\"/featured-insights/future-of-asia/future-of-asia-podcasts\\\"\\u003e\\u003cem\\u003eFuture of Asia Podcasts\\u003c/em\\u003e\\u003c/a\\u003e\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-asia/id1480316959\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/2CZX4AR2DT4hQCFKJG0cCv?si=B20tkrOmQYymuCUhKCQOwA\"}]}}},{\"mediaID\":{\"value\":\"logisticsdisruptors\"},\"title\":{\"value\":\"Logistics Disruptors\"},\"description\":{\"value\":\"Meet the companies shaping how goods will move tomorrow.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/travel logistics and infrastructure/our insights/logistics disruptors/tli-logistics-disruptors-1536x1536.jpeg\",\"alt\":\"illustration autonomous truck driving off into the future\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/travel-logistics-and-infrastructure/our-insights/logistics-disruptors\"}]}}},{\"mediaID\":{\"value\":\"mckinseyexplainers\"},\"title\":{\"value\":\"Looking for direct answers to other complex questions?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey explainers/mckinseyexplainers-flat-thumb-1536x1536.jpg\",\"alt\":\"Circular, white maze filled with white semicircles.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore the full McKinsey Explainers series\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-explainers\"}]}}},{\"mediaID\":{\"value\":\"livesandlegacies\"},\"title\":{\"value\":\"\\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-lives-and-legacies\\\"\\u003eMcKinsey on Lives \\u0026amp; Legacies\\u003c/a\\u003e\\u003c/em\\u003e\"},\"description\":{\"value\":\"Highlighting the lasting impact of leaders and executives\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey on lives and legacies/lives-and-legacies-landing-page-thumb-1536x1536.jpg\",\"alt\":\"McKinsey on Lives \\u0026 Legacies\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore previous obituaries\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-lives-and-legacies\"}]}}},{\"mediaID\":{\"value\":\"Strategy\"},\"title\":{\"value\":\"Strategy in a digital age\"},\"description\":{\"value\":\"Our series on developing corporate and business-unit strategies in a digitally disrupted world.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/our insights/strategy in a digital age/digital-strategy_1536x864_flexpromoimage.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/featured-insights/strategy-in-a-digital-age\"}]}}},{\"mediaID\":{\"value\":\"great\"},\"title\":{\"value\":\"The great re-make: Manufacturing for modern times\"},\"description\":{\"value\":\"This 21-article compendium gives practical insights for manufacturing leaders looking to keep a step ahead of today\\u0026rsquo;s disruptions.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the great remake manufacturing for modern times/jpg-ops-dm-compendium-cover-1536x864.jpg\",\"alt\":\"The great re-make: Manufacturing for modern times\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/capabilities/operations/our-insights/the-great-re-make-manufacturing-for-modern-times-compendium\"}]}}},{\"mediaID\":{\"value\":\"futureofamerica\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eFuture of America\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-america/id1616517376\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/0FpeyjojJTKf2hVtQ3otah\"}]}}},{\"mediaID\":{\"value\":\"governmentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Government\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-government/id1573645359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/61XsO4B2ersroMft8t3KSq\"}]}}},{\"mediaID\":{\"value\":\"podcast\"},\"title\":{\"value\":\"Want to subscribe to the McKinsey Podcast?\\n\"},\"description\":{\"value\":\"\\u003cdiv class=\\\"cta-container -align-horizontal\\\"\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eGoogle Play\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eiTunes\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eStitcher\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn mck-rss-icon\\\"\\u003eRSS\\u003c/a\\u003e\\n\\u003c/div\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[]}}},{\"mediaID\":{\"value\":\"operationspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Operations\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-operations/id1598128813\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/7LYQS2fxAoBmC3LgFNJbi8\"}]}}},{\"mediaID\":{\"value\":\"energyinsights\"},\"title\":{\"value\":\"Speak to an expert about our upstream capabilities\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/oil and gas/how we help clients/energy insights/newsletter-signup-promo-bar-1536x768.jpg\",\"alt\":\"EI newsletter sign up\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"buildingproductspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Building Products\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-building-product/id1735607317\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/79pncGJtBtzz7pFoR6OiH8\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/how-we-help-clients/mckinsey-academy/product-academy/mckinsey-on-building-product\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Talent\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-talent/id1491112396\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5sW4eHEFMbOvAFJjMfN9a6\"}]}}},{\"mediaID\":{\"value\":\"outlook\"},\"title\":{\"value\":\"A longer, more comprehensive version of our Global Oil Supply \\u0026 Demand Outlook is available for purchase upon request.\\n\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast2\"},\"title\":{\"value\":\"McKinsey Talks Talent Podcast\"},\"description\":{\"value\":\"Bryan Hancock, Brooke Weddle, and other talent experts help you navigate a fast-changing landscape and prepare for the future of work by making talent a competitive advantage.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/mckinsey talks talent/mck-mtt-disruptor-full-1536x864-smoke-may-2021.jpg\",\"alt\":\"McKinsey Talks Talent\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"See more episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/mckinsey-talks-talent-podcast\"}]}}},{\"mediaID\":{\"value\":\"investing\"},\"title\":{\"value\":\"Subscribe to McKinsey on Investing\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/private-capital/our-insights/mckinsey-on-investing-issue-1/contact\"}]}}},{\"mediaID\":{\"value\":\"women matter\"},\"title\":{\"value\":\"Subscribe to McKinsey \\u003cem\\u003eWomen Matter Canada\\u003c/em\\u003e\"},\"description\":{\"value\":\"Please subscribe if your organization is interested in learning about participating in future research.\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"customs\"},\"title\":{\"value\":\"This article was written as part of a larger research effort to identify opportunities for improvement and innovation at customs agencies globally.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/public-sector/our-insights/contact\"}]}}},{\"mediaID\":{\"value\":\"tech\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eCreating value beyond the hype\\u003c/span\\u003e\"},\"description\":{\"value\":\"Let\\u0026rsquo;s deliver on the promise of technology from strategy to scale.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/how we help clients/2024/never-just-tech_thumb_1536x1536.jpg\",\"alt\":\"Never just tech\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/mckinsey-digital/how-we-help-clients?cid=njt-ste-crk-mbm-mbm--2403-promo01-njt-bam-web\"}]}}},{\"mediaID\":{\"value\":\"sust\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eMove from plans to progress.\\u003c/span\\u003e\"},\"description\":{\"value\":\"Sustainability matters. Together well make it real.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/sustainability-campaign_promo-thumb_1536x1536.jpg\",\"alt\":\"Move from plans to progress.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/sustainability/how-we-help-clients/?cid=susti24-ste-crk-mbm-m01-other-glb-web\"}]}}},{\"mediaID\":{\"value\":\"nwowpodcast\"},\"title\":{\"value\":\"Subscribe to the New World of Work podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-new-world-of-work/id1319502839?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI\"}]}}},{\"mediaID\":{\"value\":\"globalpodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eThe McKinsey Podcast\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-mckinsey-podcast/id285260960?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4dyjRTP9xzEUPgleo6XjXI\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"YouTube\",\"Title\":\"\",\"Url\":\"https://www.youtube.com/@McKinsey/podcasts\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-podcast\"}]}}},{\"mediaID\":{\"value\":\"Qaudio\"},\"title\":{\"value\":\"Discover and subscribe to McKinsey Quarterly Audio\"},\"description\":{\"value\":\"\\u003cstrong\\u003eFive ways to subscribe:\\u003c/strong\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/mckinsey-quarterly-audio/id1437925222?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5mb2zYJnrPcRrML8gx5doD\"}]}}},{\"mediaID\":{\"value\":\"shortlist\"},\"title\":{\"value\":\"Subscribe to the Shortlist\"},\"description\":{\"value\":\"McKinsey\\u0026rsquo;s new weekly newsletter, featuring must-read content on a range of topics, every Friday\"},\"image\":{\"src\":\"/~/media/mckinsey/email/shortlist/template/shortlist_promo-interrupter-849120982_1536x1536.jpg\",\"alt\":\"the Shortlist\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Get the Shortlist in your inbox\",\"Title\":\"\",\"Url\":\"/user-registration/manage-account/edit-subscriptions\"}]}}},{\"mediaID\":{\"value\":\"retailpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Consumer and Retail\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-consumer-and-retail/id1526250428\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/41D4bro8PPDOGhEgOEJyHB?si=7l3SeYCZQD-7v3toqd9fHQ\"}]}}},{\"mediaID\":{\"value\":\"insurancepodcast\"},\"title\":{\"value\":\"Want to subscribe to the \\u003cem\\u003eMcKinsey on Insurance\\u003c/em\\u003e podcast?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-insurance/id1533196359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5gZ6YKF7n7C9zWaER4mFZ5\"}]}}},{\"mediaID\":{\"value\":\"strategypodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eInside the Strategy Room\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/inside-the-strategy-room/id1422814215?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4TcFfiQ0e6OYuc5kRDLxqj\"}]}}},{\"mediaID\":{\"value\":\"mgipodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eForward Thinking\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/forward-thinking/id1319502839\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI?si=0zvPmiCsQ7SBAPanfpY4aA\\u0026nd=1\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/mgi/forward-thinking\"}]}}}]},\"disruptorsignup\":{\"results\":[{\"mediaID\":{\"value\":\"full-width\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"fullwidth\"},\"value\":{\"value\":\"Full Width\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}},{\"mediaID\":{\"value\":\"left\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"left\"},\"value\":{\"value\":\"Left\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}}]}},\"ceros\":{\"results\":[]},\"exhibit\":{\"results\":[{\"id\":\"466F083F14E8463EB9B78004D7DD03B9\",\"displayName\":\"Exhibit 1\",\"mediaID\":{\"value\":\"1\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"\"}},\"displayNumber\":{\"value\":\"1\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Inflation-adjusted pharma R\\u0026D spending has outpaced clinical trial starts, with no corresponding improvement in technical and regulatory success.\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/svgz-accelerating-clinical-trials-ex1-v3.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":null,\"alt\":\"\"},\"height\":{\"value\":\"\"},\"width\":{\"value\":\"\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}},{\"id\":\"B0B16EFB19D646D3A97630939D1E5B3D\",\"displayName\":\"Exhibit 2\",\"mediaID\":{\"value\":\"2\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"\"}},\"displayNumber\":{\"value\":\"2\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Industry enrollment productivity for Phase 3 regulatory trials has declined, with sites enrolling fewer patients per month and per site.\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/svgz-accelerating-clinical-trials-ex2-v3.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":null,\"alt\":\"\"},\"height\":{\"value\":\"\"},\"width\":{\"value\":\"\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}},{\"id\":\"DE0E76050E1947C0BDEB8F3AF0E90902\",\"displayName\":\"Exhibit 3\",\"mediaID\":{\"value\":\"3\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"\"}},\"displayNumber\":{\"value\":\"3\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Demand for clinical trial patients grew by about 10 percent between 2012 and 2022.\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/svgz-accelerating-clinical-trials-ex3-v3.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":null,\"alt\":\"\"},\"height\":{\"value\":\"\"},\"width\":{\"value\":\"\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}},{\"id\":\"0D65F66181614E87A1A97D209E7F6CBB\",\"displayName\":\"Exhibit 4\",\"mediaID\":{\"value\":\"4\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"\"}},\"displayNumber\":{\"value\":\"4\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"A higher-quality investigator experience correlates with improved trial performance.\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/accelerating clinical trials to improve biopharma r and d productivity/svgz-accelerating-clinical-trials-ex4-v3.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":null,\"alt\":\"\"},\"height\":{\"value\":\"\"},\"width\":{\"value\":\"\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}}]},\"image\":{\"results\":[]},\"exhibitcarousel\":{\"results\":[]},\"pullquote\":{\"results\":[]},\"disruptorsignup\":{\"results\":[{\"mediaID\":{\"value\":\"full-width\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"fullwidth\"},\"value\":{\"value\":\"Full Width\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}},{\"mediaID\":{\"value\":\"left\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"left\"},\"value\":{\"value\":\"Left\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}}]},\"articlesidebar\":{\"results\":[{\"mediaID\":{\"value\":\"authors\"},\"description\":{\"jsonValue\":{\"value\":\"\\u003cp\\u003eThis article is a collaborative effort by \\u003ca href=\\\"/our-people/gaurav-agrawal\\\"\\u003eGaurav Agrawal\\u003c/a\\u003e, Jacob Kautzky, \\u003ca href=\\\"/our-people/harriet-keane\\\"\\u003eHarriet Keane\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/brandon-parry\\\"\\u003eBrandon Parry\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/valentina-sartori\\\"\\u003eValentina Sartori\\u003c/a\\u003e, and Amy Silverstein, representing views from McKinsey\\u0026rsquo;s Life Sciences Practice.\\u003c/p\\u003e\"}},\"aboutTheAuthors\":{\"jsonValue\":{\"value\":\"\"}},\"headline\":{\"jsonValue\":{\"value\":\"About the authors\"}},\"footnotes\":{\"value\":\"\"},\"showShareTools\":{\"boolValue\":false},\"backgroundColor\":{\"targetItem\":null},\"gradientDirection\":{\"targetItem\":{\"key\":{\"value\":\"Bottom Right\"},\"value\":{\"value\":\"bottom-right\"}}},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Collapsible\"},\"value\":{\"value\":\"default\"}}},\"isAboutAuthor\":{\"boolValue\":false},\"background\":{\"targetItem\":null},\"image\":{\"src\":null,\"alt\":\"\"}}]},\"globalsidebar\":{\"results\":[]},\"video\":{\"results\":[]},\"scrollycontainer\":{\"results\":[]},\"bespokeinteractive\":{\"results\":[]},\"storycontainer\":{\"results\":[]},\"interactive\":{\"results\":[]},\"sectionheader\":{\"results\":[]},\"statementdisruptor\":{\"results\":[]},\"fullbleedphoto\":{\"results\":[]},\"tocitem\":{\"results\":[]},\"quizcontainer\":{\"results\":[]},\"generalup\":{\"results\":[]},\"twoupmedium\":{\"results\":[]},\"accordion\":{\"results\":[]},\"factoid\":{\"results\":[]},\"promobarwithquote\":{\"results\":[]},\"oneupmedium\":{\"results\":[]},\"oneupmediumquote\":{\"results\":[]},\"gridwall\":{\"results\":[]},\"twoupsmall\":{\"results\":[]},\"oneclicksubscribe\":{\"results\":[]},\"promobar\":{\"results\":[]},\"promobanner\":{\"results\":[]},\"sectionhero\":{\"results\":[]},\"threeuplinklist\":{\"results\":[]},\"table\":{\"results\":[]},\"isFiveFiftyHorizontalArticle\":{\"boolValue\":false},\"fiveFifty\":{\"results\":[]}},\"contextItem\":{\"ancestors\":[{\"breadCrumbUrl\":{\"path\":\"/industries/life-sciences/our-insights\"},\"breadCrumbTitle\":{\"value\":\"Our Insights\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Insights on Life Sciences\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}},{\"breadCrumbUrl\":{\"path\":\"/industries/life-sciences/how-we-help-clients\"},\"breadCrumbTitle\":null,\"isMiniSite\":{\"boolValue\":true},\"displayName\":\"Life Sciences\",\"template\":{\"id\":\"414C6C64AD35440E9668CF39D8A18CCF\"}},{\"breadCrumbUrl\":{\"path\":\"/industries\"},\"breadCrumbTitle\":{\"value\":\"Industries\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Industries\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}},{\"breadCrumbUrl\":{\"path\":\"/\"},\"breadCrumbTitle\":{\"value\":\"\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Home\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}}]}}},\"placeholders\":{\"main-area\":[],\"sidebar-area\":[]}}]}},\"itemId\":\"b2fcd064-0b5a-441e-99e4-2d8a7bfc375a\",\"pageEditing\":false,\"site\":{\"name\":\"website\"},\"pageState\":\"normal\",\"language\":\"en\",\"pageMetaData\":{\"alternateLanguages\":[{\"languageCode\":\"en\",\"displayName\":\"English\",\"url\":\"/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\"}],\"currentLanguage\":\"en\",\"navigationLink\":\"industries\",\"activeItemId\":\"{BB8498AC-8CC4-4BFB-8832-53C76F3E61CF}\",\"miniSiteId\":\"{CDBF3A89-AE60-459E-ACF8-786E31307534}\",\"officeCode\":\"\",\"officeDisplayName\":\"\",\"subscriptionPracticeData\":null,\"isAlaisedPage\":false,\"originalHostName\":\"www.mckinsey.com\",\"updatedDate\":\"2024-02-13T15:33:26Z\",\"createdDate\":\"2024-01-09T15:53:24Z\",\"practice\":{\"isDefaultPractice\":false,\"name\":\"Life Sciences\",\"code\":\"N20\",\"stickyTitle\":\"Sign up for emails on new Life Sciences articles\",\"stickySubtitle\":\"Never miss an insight. We'll email you when new articles are published on this topic.\",\"previewLink\":\"\",\"previewLinkLabel\":\"Preview\",\"description\":null,\"descriptionText\":\"Get the latest articles on this topic delivered to your inbox\",\"frequency\":\"Alert\",\"regFormTitle\":null},\"url\":\"/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity\",\"isCareersPage\":false,\"officePath\":\"\",\"hideAppPromo\":false,\"itemInfo\":{\"id\":\"b2fcd064-0b5a-441e-99e4-2d8a7bfc375a\",\"fullPath\":\"/sitecore/content/McKinsey/Home/Industries/Life Sciences/Our Insights/Accelerating clinical trials to improve biopharma R and D productivity\",\"templateName\":\"ArticleJSS\",\"templateID\":\"683910db-02ba-40ba-92e7-726c880160a9\"}},\"defaultSettings\":{\"McKinsey Quarterly\":\"\\u003cem\\u003eMcKinsey Quarterly\\u003c/em\\u003e\",\"FacebookCID\":\"soc-web\",\"LinkedInCID\":\"soc-web\",\"TwitterCID\":\"soc-web\",\"Home Page SEO Details\":{\"Description\":\"McKinsey \\u0026 Company is the trusted advisor and counselor to many of the world's most influential businesses and institutions.\",\"Image_Url\":\"/~/media/images/global/seoimageplaceholder.jpg\",\"Image_Alt\":\"\"}},\"alumniDatalayerChunk\":\"static/chunks/alumnidatalayer.2eb8cbe055d39895.js\"},\"componentProps\":{},\"notFound\":false,\"noAccess\":false},\"__N_PREVIEW\":true,\"__N_SSP\":true},\"page\":\"/[[...path]]\",\"query\":{\"timestamp\":\"1729755769980\",\"path\":[\"middle-east\",\"ar\",\"our-insights\",\"how-ceos-can-mitigate-compounding-risks\"]},\"buildId\":\"AymXir4ImcRSnB3UIpSL6\",\"runtimeConfig\":{\"CONFIG_ENV\":\"production\",\"CURRENT_ENV\":\"production\",\"PUBLIC_URL\":\"https://www.mckinsey.com\",\"PUBLIC_CMS_URL\":\"https://cms-prod.mckinsey.com\",\"RECAPTCHA_V3_KEY\":\"6LdC5twSAAAAAF0dePIbY_ckeF05mKdYYJXn7uTg\",\"INVISIBLE_RECAPTCHA_KEY\":\"6LcWCs0UAAAAAEik2NaGkfGH8mGHo1ThxIt-qUoE\",\"USER_SERVICE_API_HOST\":\"https://prd-api.mckinsey.com\",\"MOBILE_SERVICES_HOST\":\"https://mobileservices.mckinsey.com\",\"SEARCH_SERVICE_API_HOST\":\"https://mckapi.mckinsey.com\",\"OT_DATA_DOMAIN_SCRIPT_COM\":\"915b5091-0d7e-44d2-a8c4-cf08267e52fe\",\"OT_DATA_DOMAIN_SCRIPT_DE\":\"13f50396-9d33-4d95-ba3e-1f108fa91009\",\"OT_DATA_DOMAIN_SCRIPT_BR\":\"679eae24-1d5c-4f33-8aae-b35aa8269966\",\"ADOBE_LAUNCH\":\"a400cfbb2fd3\",\"BCOV_POLICY\":\"BCpkADawqM3Xn1B8iTmHawNytUSk0kXaQKMSM51CBVsYKHfwlRhZimTJqbOOq0NuyxTKQnvb4V9myMVRjwGkyGtJQO2HrUPOJHcsgkpbB-jyHwswonskf6XnZaF0TyyKkAQgbymSMtudeD9CLk-xCpqAzTaNUm7a3M3QKLN4pdLRNJ9_HbVMWzNpiUr5ezAVdMciDMwsD-gxNl43d7bfVP3wRhTNWbWUYn3WK7-Oz2gbxV6mMTm0jJU3SjK_x0meTprYUgdUWA-iDgwVglsnfJ_SVtVDPZypUokKv85GzFLM-ywjWlPM2Hg1ucemwwOpa-qvYBGfeMV7zP3n6s22hFCBveiWtHEBpV9N8f4rjmunMlxBx7kSlxIRjWquZm70hLRXMoxAgQ22BC86tBhgR_d1l9_-FzZuZIlZhzJwJi3ug1HszooHM8uEMOkHmB5nYj5XEgVk5JFYGcSwFSnMnNzE1ej2J3jcEiE3eSWHcremWjCZ0s9bs_8R08WpGWkBp8WMXUFfmhPBMk-MGixR_yIu7nJ6B_hYBnVhqKnnoW-xxEmRxgwG0Ev0S96cAcBG8qdlChGN7o1qN0heGTUIYnDk703q3lt9j7X4FgaITrlcPZOWZ96EHytVKUAtmtVp5BVGpiLn4viuUpEdAM_CLSBIaPVunk-39L8tm6m8iUYmbMX_KXPyaL900bQtVQgK39FCa0pUEZ_jSBOGNj1FH8NUPN2TS8_csNWfpN7gsaD9FBN3wUtawAD_RPdJ952odfwJqyvrkN89AyKnFdFMvUh6_4LCIQVYd4M5KC_k1WNLYb11KZhq6O4UaoyD4X1pV4-x0jBzEnc4VQTkL_04dw2xdPJ1uqUrmHuUcIBO0SKaEk6_5HYc3GKfYwmPz1oxMpOi-Rzw1QPyWIdbrcZdFbIHoVZ8FKfyslEv392pJMiKzUnVWL_3mZ0UqnGtddwlXYVdSs57AUdlrfOe7TVaaIMZ_kL7FSrbWrsaSufitSYr62xD1K1-qeb4wkx8QQEorxGJ3RG1Vpn97Pn5JEC_jvj0s7uzFgidYR9bp80EMmPCHUmRg-Hm1Aq1B4YMNc1ARnFz6UvT_8_pMhJEwKuypA-nPoJu4JZJNLVUdw\",\"sitecoreApiKey\":\"{AD59BE63-BA20-47D4-A1B0-ECF30588E2E2}\",\"sitecoreApiHost\":\"https://prod.mckinsey.com\",\"FB_APP_ID\":\"1382278882079245\",\"ARTICLE_API_HOST\":\"https://prd-api.mckinsey.com\",\"SITECORE_FORMS_SERVICES_API_HOST\":\"https://prd-api.mckinsey.com\",\"FEATURE_TOGGLES\":\"{\\\"stack_adapt_pixel\\\": true, \\\"article_seo_schema\\\":true, \\\"remember_me\\\": true, \\\"gql_promo_banner\\\": true, \\\"gql_highlight_bar\\\": true, \\\"gql_ceros_placeholder\\\": true, \\\"gql_two_up_medium\\\": true, \\\"gql_hero_with_partnership_mark\\\": true, \\\"gql_brightcove_gallery\\\": true, \\\"gql_one_up_medium\\\": true, \\\"gql_promo_bar_with_quote\\\": true, \\\"gql_fifty_fifty_hero\\\": true, \\\"gql_enhanched_hero\\\": true, \\\"gql_two_up_small\\\": true, \\\"gql_general_up\\\": true, \\\"gql_full_bleed_hero\\\": true, \\\"passwordless_login_enabled\\\": true, \\\"sso_enabled\\\": true, \\\"article_id\\\": \\\"\\\", \\\"personalisation_enabled\\\":true, \\\"hide_student_sticky_footer\\\":true, \\\"email_domain_validation_enabled\\\":true}\",\"HEADER_SCRIPT_HASH\":\"abcd1234\",\"OKTA_AUTH_CLIENT_ID\":\"0oa8ppb3ypQ8uOI8y697\",\"OKTA_AUTH_ISSUER\":\"https://dotcomidp.mckinsey.com/oauth2/aus2byav0jTElyFDD697/\",\"AUTO_REDIRECTION_DURATION\":\"5\",\"LINKEDIN_IDP\":\"0oaecyj1byxnfrfFk697\",\"APPLE_IDP\":\"0oaeg2lxy6mq4PX5F697\",\"GOOGLE_IDP\":\"0oaeczfkb03XL3E4O697\",\"ALUMNI_BASE_API_URL\":\"https://dev-gateway.intranet.mckinsey.com/:apiKey/v1\",\"ALUMNI_AUTHENTICATE_API_URL\":\"https://dev-ac3-okta-auth.intranet.mckinsey.com/authenticate\",\"ALUMNI_OKTA_URL\":\"\",\"ALUMNI_OKTA_ENABLED\":\"true\",\"GOOGLE_MAP_API_KEY\":\"AIzaSyDqrGDNMDjy9pXHkMf-_Ut33LoC725GSe4\",\"AWS_GATEWAY\":\"https://dev-gateway.mckinsey.com\",\"AWS_API_GATEWAY_ID\":\"o63viscaj4\",\"AWS_PERSONALIZATION_TRACKING_ID\":\"f3f97bc3-4ca7-4960-9e49-0bcff6294ab4\",\"AWS_PERSONALIZATION_CID\":\"recommendations-onw-onw-mck-mck-art-2410-v1-user-ext-web\",\"EVENTS_MODULE_CARDS_COUNT\":\"8\",\"RECOMMENDATIONS_OFFER_ACTIVITY\":\"Article Recommendations\"},\"isFallback\":false,\"dynamicIds\":[70281,79556,76731,42354,35278,68578,98391],\"gssp\":true,\"locale\":\"en\",\"locales\":[\"en\",\"da-DK\"],\"defaultLocale\":\"en\",\"isPreview\":true,\"scriptLoader\":[]}</script><script type=\"text/javascript\" src=\"/1sISTh/L/u/nAoEgpNcfg7J/GaO3tL2mVXLX7b/BVlZblY_cBA/SXAe/KgkXcSUB\"></script><div id=\"floating-ui-root\"></div><script src=\"https://assets.adobedtm.com/b0dfb38aec8a/63974894e9a9/launch-a400cfbb2fd3.min.js?l=1\" data-nscript=\"afterInteractive\"></script><script id=\"data-layer\" data-nscript=\"afterInteractive\">eventDataLayer.pageLoadCompleted()</script><next-route-announcer><p aria-live=\"assertive\" id=\"__next-route-announcer__\" role=\"alert\" style=\"border: 0px; clip: rect(0px, 0px, 0px, 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap; overflow-wrap: normal;\"></p></next-route-announcer></body></html>"
}